Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 1of 95Clinical Study Protocol 
Study Intervention AZD8233
Study Code D7990C00003
Version 2.0
Date 16Dec 2020
A Rando mized, Parallel, Double -blind, Placebo -controlled, Dose -ranging, Phase 2b Study  to 
Evaluate the Efficacy , Safety and T olerabili ty of AZD8233 Treatment in Participants W ith 
Dyslipi[INVESTIGATOR_694640]: [COMPANY_008] AB
Legal Registered Address: 151 85 Södertälje, Sweden
Regulatory Agency Identifier  Number(s): EudraCT number 2020-000767-[ADDRESS_942274] procedures. The Clinical Study Protocol is publicly registered, and the results are 
disclosed and/or published according to the [COMPANY_008] Global Policy on Bi oethics and in 
compliance wi th prevailing laws and regulat ions.
Protocol Number: 2.0
Amendment Number: 1
Study  Intervent ion: AZD8233
Study  Phase: Phase 2b
Short Title: A Phase 2b Study  of AZD8233 in Parti cipants W ith Dyslipi[INVESTIGATOR_694641] -2.[ADDRESS_942275] ivities....................................................................................... 11
2. INTRODUCTION ............................................................................................ 19
2.1 Study  Rati onale ................................................................................................ 19
2.2 Background ...................................................................................................... 19
2.3 Benefit/Risk Assessment ................................................................................... 19
2.3.1 Risk Assessment ............................................................................................... 20
2.3.2 Benefit Assessment ........................................................................................... 23
2.3.3 Overall Benefit/Risk Conclusio n....................................................................... [ADDRESS_942276] ions................................
.................................................. 32
5.3.5 Blood donati on................................................................................................. 33
5.4 Screen Failures ................................................................................................. 33
6. STUDY  INTER VENTION ............................................................................... 34
6.1 Study  Intervent ion(s) Administered ................................................................... [ADDRESS_942277] igational Products .................................................................................... 34
6.2 Preparati on/Handling/Storage/Accountabilit y of Intervent ions.......................... 35
6.3 Measures to Minimise Bias: Rando mization and Blinding ................................ 35
6.4 Study  Intervent ion Compliance ......................................................................... 36
6.5 Concomitant Therapy ........................................................................................ 37
6.5.1 Rescue Medicine ............................................................................................... 38
6.6 Dose Mod ificat ion............................................................................................ 38
6.7 Intervention after the End of the Study .............................................................. 38
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 3of 957. DISCONTINUA TION OF STUDY  INTER VENTION AND PARTICIPANT 
DISCONTINUA TION/WITH DRA WAL........................................................... [ADDRESS_942278] ing AE and SAE Informat ion................ 48
8.3.2 Follow-up of  AEs and SAEs ............................................................................. 48
8.3.3 Causalit y Collection.......................................................................................... 49
8.3.4 Adverse Events Based on Signs and Symptoms ................................................ 50
8.3.5 Adverse Events Based on Examinat ions and T ests............................................ 50
8.3.6 Hy’s Law .......................................................................................................... 50
8.3.7 Reporting of Serious Adverse Events ................................................................ 51
8.3.8 Pregnancy ......................................................................................................... 51
[IP_ADDRESS] Maternal E xposure ............................................................................................ 51
[IP_ADDRESS] Paternal  Exposure ............................................................................................. 52
8.3.9 Medicat ion Error ............................................................................................... 52
8.4 Overdose .......................................................................................................... 53
8.5 Hum an Bi ological  Samples ............................................................................... 53
8.5.1 Pharmacokinet ics.............................................................................................. 54
[IP_ADDRESS] Determinat ion of Drug Concentration ............................................................... 54
8.5.2 Immunogenicit y Assessments ........................................................................... 55
8.5.3 Pharmacodynamics ........................................................................................... 55
[IP_ADDRESS] Collect ion of Samples ....................................................................................... [ADDRESS_942279] ion of Mandatory  Samples for Bi omarker Analysis ................................ 56
8.7 Optional Genomics Ini tiative Sample ................................................................ 56
8.8 Health Economics ............................................................................................. 57
9. STATISTICAL  CONSIDER ATIONS ................................................................ 57
9.1 Statistical Hypotheses ....................................................................................... 57
9.2 Sample Si ze Determinat ion............................................................................... 57
9.3 Popul ations for Analyses ................................................................................... 58
9.4 Statistical Analyses ........................................................................................... 58
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 4of 959.4.1 General Considerations ..................................................................................... 58
9.4.2 Efficacy ............................................................................................................ 59
[IP_ADDRESS] Primary En dpoint(s) .......................................................................................... 59
[IP_ADDRESS] Secondary  Endpo int(s)...................................................................................... [ADDRESS_942280] ivities (SoA) .................................................................... [ADDRESS_942281] OF APPENDICES
Appendix A Regulatory , Ethical , and Study  Oversight Consi derati ons......................... 62
Appendix B Adverse Events: Definit ions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting ........................................................................ 67
Appendix C Handling of Human Bio logical  Samples .................................................. 72
Appendix D Optional Genomics Ini tiative Sample ....................................................... 74
Appendix E Actions Required in Cases of Increases in Liver Biochemistry  and 
Evaluat ion of Hy’s Law ........................................................................... 78
Appendix F Actions in Case of Development of Thrombocy topenia or 
Uninterpretable Platelet Counts After Administration of ASOs ................ 83
Appe ndix G Guidance for Definit ion of Anaphylactic/Hypersensit ivity React ions and 
Checklist for the Invest igator ................................................................... [ADDRESS_942282] 80 evaluable participants completed treatment up until and including visit 10 (week 12). 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 9of 95Note : "Enrolled" means a participant's, or their legally acceptable representative ’s, agreement 
to parti cipate in a clinical study  following com pletion of the informed consent process. 
Potenti al parti cipants who are screened for the purpose of determining eligibilit y for the study  
but are not randomly assigned/assigned in the study , are considered “screen failures ”, unless 
otherwi se specified by  [CONTACT_760] . 
Intervention Groups and Duration:
The screening period starts up to 42 days before the randomization visit and ends on Day  -1. 
Eligible participants will attend 7 visits during the treatm ent peri od and 7 addi tional visits 
during the safet y follow up peri od. Eligible participants are randomized across four different 
treatm ent arm s at a 1:1:1:1 ratio for a 12 -week treatment period. The planned treatment arms 
are: AZD8233 , AZD8233 , AZD8233 , and Placebo. Participants will be 
dosed SC on Day s 1, 8, 29, and 57. 
Data Monitoring Committee:
A data m onitoring committee will not be used in this study .
Statistical methods
The primary  object ive of this study  is to com pare abso lute change from  baseline in 
log-transform ed LDL -C across different dose levels of AZD8233. 
The key  secondary  object ive of this study  is to compare abso lute change form baseline in 
log-transform ed PCSK9 across different dose levels of AZD8233.  
Both l og-transformed LDL -C and l og-transform ed PCSK9 will be analysed by  [CONTACT_6486] a mixed 
model for repeated m easures to the data with baseline as covariate and treatment, time (visit 
number), and interaction between treatment and time as factors.
The parti cipants wil
l be analysed according to the treatment to which the participant was 
rando mised. Participants will be analysed with respect to the intention to treat principle using 
the full analysis set which contains data fro m each parti cipant who received at least one dose 
of placebo or AZD8233.
Key safet y object ive is overall tolerabilit y, which will be presented with descript ive statist ics.
CCI
CCI
CCI
Clinical Study Prot ocol -2.[ADDRESS_942283] been performed and all 
inclusio n/excl usioncriteria as well  as other protocol  restri ctions have been evaluated; see 
Secti ons [ADDRESS_942284] igator has 
determined that the results are within acceptable range according to the defined stoppi[INVESTIGATOR_31732]; see Section 7.1. Laboratory  assessment resul ts shoul dalso be reviewed at every  visit 
to ensure that stoppi[INVESTIGATOR_27445]. 
Assessments scheduled at the same t ime may be initiated based on the sequence below:
1ECG
2Vital signs (SBP and diastolic blood pressure [DBP]), pulse rate, and temperature, if 
appropriate)
3PK and PD blood sampling
4Dose administration
Pre-dose assessments may be performed up to 60 minutes prior to dosing.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 12of 95Table1 Schedule of Activities (SoA)
Screening Treatment Period EDVSafety 
Follow -
up 
periodFinal 
Follow -
up 
VisitDetails in 
CSP Section 
or Appendix
Visit Number 1 2 3 4 5a6 7a8 9a10, 11a, 
12, 13a, 
14, 15a16
Study  Week 0 1 3 4 6 8 1012, 14, 
16, 18, 
20, 2224
Study  DayD-42 to 
D-1lD-7 to 
D-1D1 D8 D22 D29 D43 D57 D71D85, 
D99, 
D113, 
D127, 
D141, 
D155D169
Visit Window± 1 
days± 2 
days± 2 
days± 2 
days± 2 
days± 2 
days± 2 
days± 2 
days
Informed consent X Appendix A 3
Optional Informed 
consent for future genetic 
research sampleX Appendix D
Verify eligibility criteria X Xb Sections 5.1, 
5.2
Enrolment in RTSM X Sections 6.3, 8
Randomisation in RTSM X Sections 6.3, 8
Medical history X Section 8
Concomitant medication 
reviewX X X X X X X X X X X XSection 6.5
Demographics X Section 9.4.1
Height X

Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 13of 95Table1 Schedule of Activities (SoA)
Screening Treatment Period EDVSafety 
Follow -
up 
periodFinal 
Follow -
up 
VisitDetails in 
CSP Section 
or Appendix
Visit Number 1 2 3 4 5a6 7a8 9a10, 11a, 
12, 13a, 
14, 15a16
Study  Week 0 1 3 4 6 8 1012, 14, 
16, 18, 
20, 2224
Study  DayD-42 to 
D-1lD-7 to 
D-1D1 D8 D22 D29 D43 D57 D71D85, 
D99, 
D113, 
D127, 
D141, 
D155D169
Visit Window± 1 
days± 2 
days± 2 
days± 2 
days± 2 
days± 2 
days± 2 
days± 2 
days
Body weightcX X X X X X X Section 8.2.1
BMI X X X Section 8.2.1
HbA1c X Section 8.2.5
Viral serology X Section 8.2.5
Pregnancy and 
reproductive status 
(females only, pre -dose)X XSection 8.2.4
Study intervention 
administration 
(AZD8233/Placebo)X X X XSection 6.1.1
Safety Assessments
Adverse event reviewX (SAE 
only)X (SAE 
only)X X X X X X X X X XSection 8.3

Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 14of 95Table1 Schedule of Activities (SoA)
Screening Treatment Period EDVSafety 
Follow -
up 
periodFinal 
Follow -
up 
VisitDetails in 
CSP Section 
or Appendix
Visit Number 1 2 3 4 5a6 7a8 9a10, 11a, 
12, 13a, 
14, 15a16
Study  Week 0 1 3 4 6 8 1012, 14, 
16, 18, 
20, 2224
Study  DayD-42 to 
D-1lD-7 to 
D-1D1 D8 D22 D29 D43 D57 D71D85, 
D99, 
D113, 
D127, 
D141, 
D155D169
Visit Window± 1 
days± 2 
days± 2 
days± 2 
days± 2 
days± 2 
days± 2 
days± 2 
days
Injection site reactions dX X X X X X X X X X Section 8.2.6
Complete physical 
examinationX X X XSection 8.2.1
Abbreviated physical 
examinationX X X X X X XSection 8.2.1
Vital signs (blood 
pressure, pulse and 
temperature) eX X X X X X X X X X XSection 8.2.2
ECG eX X X X X X XfX Section 8.2.3
Serum chemistry X X X X X X X X X X X Section 8.2.4
Hematology X X X X X X X X X X X Section 8.2.4
Coagulation parametersgX X X X X X X X X X X Section 8.2.4
hs-CRP X X X X X X Section 8.2.4

Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 15of 95Table1 Schedule of Activities (SoA)
Screening Treatment Period EDVSafety 
Follow -
up 
periodFinal 
Follow -
up 
VisitDetails in 
CSP Section 
or Appendix
Visit Number 1 2 3 4 5a6 7a8 9a10, 11a, 
12, 13a, 
14, 15a16
Study  Week 0 1 3 4 6 8 1012, 14, 
16, 18, 
20, 2224
Study  DayD-42 to 
D-1lD-7 to 
D-1D1 D8 D22 D29 D43 D57 D71D85, 
D99, 
D113, 
D127, 
D141, 
D155D169
Visit Window± 1 
days± 2 
days± 2 
days± 2 
days± 2 
days± 2 
days± 2 
days± 2 
days
Complement activation 
panel gX X X XSection 8.2.4
Urinalysis X X X X X X X X X X X Section 8.2.4
Urine renal safety 
biomarkersX X X X X X X X X X X Section 8.2.4
Pharmacodynamics
LDL -C hX X X X X X X X X X X Section [IP_ADDRESS]
PCSK9 hX X X X X X X X X X X Section [IP_ADDRESS]
Triglycerides hX X X X X X X X X X X Section [IP_ADDRESS]
Other Lipid parameters hX X X X X X X X X X Section [IP_ADDRESS]
Lipoprotein profile hX X X X X X X X X X Section [IP_ADDRESS]

Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 16of 95Table1 Schedule of Activities (SoA)
Screening Treatment Period EDVSafety 
Follow -
up 
periodFinal 
Follow -
up 
VisitDetails in 
CSP Section 
or Appendix
Visit Number 1 2 3 4 5a6 7a8 9a10, 11a, 
12, 13a, 
14, 15a16
Study  Week 0 1 3 4 6 8 1012, 14, 
16, 18, 
20, 2224
Study  DayD-42 to 
D-1lD-7 to 
D-1D1 D8 D22 D29 D43 D57 D71D85, 
D99, 
D113, 
D127, 
D141, 
D155D169
Visit Window± 1 
days± 2 
days± 2 
days± 2 
days± 2 
days± 2 
days± 2 
days± 2 
days
Pharmacokinetics
PK plasma sample iX X X X X X X iX Section 8.5.1
Immunogenicity
Samples for anti -
AZD8233 antibodies jX X X X X X jX Section 8.5.2
Exploratory biomarker analysis
Biomarker analyses 
(plasma)hX X X X X X X X X X X Section 8.6.1
Biomarker analyses 
(urine)hX X X X X X X X X X Section 8.6.1
Genomics Initiative 
optional, exploratory 
genetic sample kX Section 8.7

Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 17of 95Table1 Schedule of Activities (SoA)
Screening Treatment Period EDVSafety 
Follow -
up 
periodFinal 
Follow -
up 
VisitDetails in 
CSP Section 
or Appendix
Visit Number 1 2 3 4 5a6 7a8 9a10, 11a, 
12, 13a, 
14, 15a16
Study  Week 0 1 3 4 6 8 1012, 14, 
16, 18, 
20, 2224
Study  DayD-42 to 
D-1lD-7 to 
D-1D1 D8 D22 D29 D43 D57 D71D85, 
D99, 
D113, 
D127, 
D141, 
D155D169
Visit Window± 1 
days± 2 
days± 2 
days± 2 
days± 2 
days± 2 
days± 2 
days± 2 
days
Note: Participants are required to fast for at least 8 hours overnight prior to all study visits except for Visit 1; Particip ants are permitted to drink water during 
this period of fasting until 1 hour before blood sampling. On days where participants attend the clinic in a fasted state, blood and urine samples s hould be 
obtained prior to administration of IP.
Note: Samples to be obtained from all treatment arms unless specified in the table.
aHome visits: may be undertaken at the participant’s home or any other appropriate location by [CONTACT_694656]. Other 
visits currently not designated as ‘home visits’ may also be undertaken at the participant’s ho me or any  other appropriate location if deemed applicable, 
following consultation with the Investigator and the sponsor. Home visits performed by [CONTACT_694657] (i .e. not by [CONTACT_694658]) may only be performed starting Visit 5 (D22) , excluding dosing visits ( Visit 6 (D29) and Visit 8 (D57) ).
bCheck screening labs and inclusion/exclusion criteria.
cWeight should be measured in light indoor clothes, without shoes, after a prior visit to the bathroom.
dInjection Site Reaction assessments to be collected based on adverse event collection criteria.
eVital signs and ECG to be measured pre -dose on dosing days.
fECG to be performed during the safety follow up period at Visits 10 (D85), 11 (D99), 13 (D127), and 15 (D155).
gBlood sample s for complement activation panel and coagulation parameters will be taken around Cmax and are to be collected pre -dose and [ADDRESS_942285] -
dose.
hSamples to be obtained pre -dose on dosing days.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 18of 95Table1 Schedule of Activities (SoA)
Screening Treatment Period EDVSafety 
Follow -
up 
periodFinal 
Follow -
up 
VisitDetails in 
CSP Section 
or Appendix
Visit Number 1 2 3 4 5a6 7a8 9a10, 11a, 
12, 13a, 
14, 15a16
Study  Week 0 1 3 4 6 8 1012, 14, 
16, 18, 
20, 2224
Study  DayD-42 to 
D-1lD-7 to 
D-1D1 D8 D22 D29 D43 D57 D71D85, 
D99, 
D113, 
D127, 
D141, 
D155D169
Visit Window± 1 
days± 2 
days± 2 
days± 2 
days± 2 
days± 2 
days± 2 
days± 2 
days
iPK sampling to be performed at Visits 4 (D8), 6 (D29), 7 (D43), 8 (D57), 9 (D71), 10 (D85), 12 (D113) and 14 (D141) and final follow -up visit/EDV. 
Schedule of sampling for Visits 4 (D8), 6 (D29), 8 (D57) are shown below.
Visit 4 (Day 8; Loading dose): pre -dose
Visit 6 (Day 29; Dose 3): pre -dose
Visit 8 (Day 57; Final dose): pre -dose
jADA sampling to be performed at Visits 3 (D1), 4 (D8), 6 (D29), 8 (D57), 10 (D85), 12 (D113), and 14 (D141), and final follow -up visit/EDV. ADA 
samples to be collected pre -dose on all dosing days.
kIf, for any reason, the sample is not draw n pre -dose on Visit 3 (D1), it may be taken at any visit until the Final follow -up/EDV visit.
lVisit 1 and visit 2 may be combined. 
BMI = body mass index; CSP = clinical study protocol; D = day; ECG = electrocardiogram; EDV = early discontinuation visit; H bA1c = haemoglobin A1c; 
LDL -C =low -density  lipoprotein cholesterol; PCSK9 = proprotein convertase subtilisin/kexin type 9; RTSM = Randomization and Trial Supply Management.
Clinical Study Protocol -2.[ADDRESS_942286] to diet. Reduction o f LDL -C by  [CONTACT_694659] a 
significant reduction in cardiovascular events ( Collins R et al 2016). Statins reduce LDL -C 
by [CONTACT_694660] -CoA reductase, the rate -limiting enzyme of hepa tic cholesterol  synt hesis. 
However, despi[INVESTIGATOR_694642] o f statin therapy , many  patients do not reach LDL -C 
target goals and some continue to be at residual CVD risk despi[INVESTIGATOR_694643].
Genet ic studies have ident ified PCSK9 as an important, HMG -CoA-independent circulat ing 
regul ator of LDL- C (Cohen J et al 2005 , Cohen J et al 2006 ). Gain of funct ion mutati ons in 
PCSK9 cause familial hypercho lesterol emia; l oss of  function is associated with low 
circulat ing levels of LDL -C and a reduced risk of major vascular events. Mole cularly , 
circulat ing PCSK9 is derived mainly fro m the liver and increases LDL -C by  [CONTACT_694661]. 
Two monocl onal antibodies (evo locumab [[COMPANY_010]] and alirocumab [Sano fi/Regeneron]) have 
been successfully developed to pharmac ologically inhibi t circulat ing PCSK9. Inject ion of 
these compounds lowers LDL -C levels by  [CONTACT_3450] 60%, even in clinical study  
participants al ready  receiving maximum  dose stati n therapy  (Sabatine MS et al 2017, Ray 
KK et al 2017 ). Based on the significant clinical benefit of PCSK9 inhibit ion, AstraZe neca is 
developi[INVESTIGATOR_007] a PCSK9 -targeted, N -acetylgalactosamine -conjugated ASO specifically inhibit ing 
intracellular PCSK9 expressio n in the liver ( Prakash TP  et al 2014 ). AZD8233 may provide 
novel treatment options for participants with dyslipi[INVESTIGATOR_035].
Adetailed description o f the chemistry , pharm acology , efficacy , and safet y of AZD8233 is 
provi ded in the Invest igator ’s Brochure ( Investigator ’s Brochur e 2019 ).
2.3 Benefit/Risk Assessment
Potenti al risks of AZD8233 and mit igation strategy  are shown in Table 2. More detailed 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 21of 95Potential Risk of Clinical 
SignificanceRationale for RiskMitigation Strategy (refer to IB 
Section 5.5 for further detail)
in the non -clinical toxicology 
studies.
Anti -drug Antibodies There is a potential risk for 
antibody formation. Emergence of 
ADA has been observed in a 
proportion of clinical study 
participants after repeated 
oligonucleotide treatment, leading 
to change in PK profile. To date, 
no apparent association of ADA 
with loss of efficacy or safety 
findings have been observed.Assessment of ADAs and 
monitoring for immunogenicity 
effects (including hypersensitivity 
reactions and ADA effect on 
PK/PD). Guidance on the 
definition of an anaphylactic 
reaction and the action plan that 
needs to be followed with regards 
to ADA sampling is presented in 
Appendix G.
Injection Site ReactionsAs with any exogenous substance, 
injection site reactions may occur 
as a response to the SC injection 
of AZD8233. Possible risks 
associated with SC administration 
are redness, swelling, pain, 
induratio n, and sometimes 
infection at the administration site. 
Although observed for some 
ASOs, injection site reactions are 
not generally a clinical problem 
for newer generation ASOs.Monitor ing for injection site 
reactions
Complement ActivationThis is a known class effect of 
oligonucleotides and appears to be 
directly plasma concentration 
(Cmax) driven. Monkey s are 
considered more sensitive to 
complement activation than 
humans (Crooke ST et al 2016 ). 
No indication of complement 
activatio n induced by  [CONTACT_99213]8233 
have been observed in toxicology 
studies.Assessment of complement 
activatio n around Cmax(C3a, C5a, 
Bb)
Increased Bleeding RiskIncreases in aPTT, in the absence 
of clinical or pathological 
sequelae, have been observed with 
ASOs ( Burel S et al 2013 , Henry 
SP et al 1997 ). Mechanistically, 
interaction of ASOs with the 
intrinsic tenase complex and 
thrombin results in a selective 
inhibition of the intrinsic clotting Assessment of aPTT and PT
Clinical Study Protocol -2.[ADDRESS_942287] 
been well -tolerated wi th no parti cular safet y findings. Doses of  were efficacious in 
lowering PCSK9 by  ≥ 90% and LDL  by [CONTACT_422906]  70% (Study  D7990C00001).
A multiple ascending dose study  of AZD8233 is ongo ing (Study  D7990C00002).
Consequent ly, AZD8233 is expected to lower circulat ing PCSK9 in this study in all 
participants (see Section 4.3). Pharmaco logic inhibit ion of PCSK9 is known to increases the 
catabolism o f LDL -C and reduce circulat ing LDL -C significant ly. Low l evels of LDL -C are 
associ ated wi th a monotoni cally  lower risk of incident atherosclerotic CVD events, providing 
an important clinical benefit to patients with dyslipi[INVESTIGATOR_035].
A detailed descript ion of the chemistry , pharmaco logy, efficacy , and safet y of AZD8233 is 
provided in the Invest igator ’s Brochure.
2.3.3 Overall Benefit/Risk Conclusion
Taking into account the measures taken to minimise risk to the participants of this study , the 
potenti al risks i dentified in associat ion with AZD8233 are just ified by [CONTACT_694662][INVESTIGATOR_035].
CCI
CCI
Clinical Study Protocol -2.[ADDRESS_942288] between -7 to -1 day s prior to 
rando mizat ion. Eligible participants will attend 7 visit s during the treatment period and 7 
additional visits during the safety  follow up peri od. Eli gible partici pants are randomized 
across four different treatment arms in a 1:1:1:1 ratio for a 12 -week treatment period. The 
planned treatm entarms are AZD8233 
 SC, AZD8233  SC, AZD8233  SC, 
and Placebo SC on Day s 1, 8, 29, and 57. 
This study  is doubl e-blind with regards to treatment (AZD8233 or placebo) at each dose level. 
AZD8233 and placebo will be matched for appearance. Part icipants rando mized to placebo 
will receive a vo lume of inject ion that will not differ substant ially fro m participants on active 
drug. From rando mizat ion, every  second visit is planned to be a site visit and the visits in -
between m ay be ho me visits. Home visit s are opti onal, and all visit s coul d be conducted as on -
site visi ts, if this is preferred. Home visits may be undertaken at the participant ’s home or any  
other appropriate location by [CONTACT_694663] . Other visi ts that
are currently not designated as ‘home vis its’ may also be undertaken at the participant ’s home 
or at any  other appropri ate locati on if deemed applicable, fo llowing consultat ion with the 
Invest igator and the sponsor . Home visit s performed by  [CONTACT_694664] 
(i.e. not by  [CONTACT_694665]) may only  be perform ed starting V isit 5 (D22) ,
excluding dosing visits ( Visit 6 (D29) and V isit 8 (D57) ).
After the treatment period, participants will continue in a safet y follow up peri od of  12 weeks 
(up to [ADDRESS_942289] dose). 
For detailed informat ion please refer to the SoA  (Table1).
4.[ADDRESS_942290] a 
therapeuti c dose for further clinical development.
The scheduled 12 weeks dosing should be sufficient to reach close to steady state condit ions 
in the t issues at the end of the dosing period (estimated terminal half- life of the full length 
ASO in plasma is 2- 3 weeks). Based on these data and the expected time course for PCSK9 
and LDL -C reducti on, [ADDRESS_942291] been well tolerated in participants wi th 
elevated LDL -C (Study  D7990C00001). The doses for the current study  have been selected 
based on observed PCSK9 and LDL -C reducti on in the single ascending dose study  
(D7990C00001) and the predicted PCSK9 and LDL  reducti on at steady  state of the selected 
doses taking expected accumulation into account for a Q4W  dosing regimen that includes a 
loading dose at Day  8. The mid and high dose, planned to  and  (Day s 1, 8, 29, 
and57) were sel ected to achieve a PCSK9 reduction of around 90% during the dose interval 
and is expected to result in clo se to m aximum achievable effect in terms of LDL -C reducti on, 
with the aim  to show that an increase in dose above the mid dose will not result in a clinically  
significant further reduction in LDL -C. The low dose, pl anned to  (Days 1, 8, 29, 
and57) was selected to reach a PCSK9 reduction of below 80% over the ent ire dose interval 
and was selected to show that decreasing the dose and PCSK9 -reducti on to bel ow 80% will  
lead to a clinically  significan t lower LDL -C reductio n as co mpared to the mid dose. The mid 
dose was thus selected to be in the therapeutic dose range. Prior to the start of dosing in the 
current study , safet y data after two repeated doses of AZD8233  (in 
Study D7990C00002) as well as safet y and potentially  PCSK9 and LDL -cholesterol data after 
repeated (Day s 1, 8, 29, and 57) dosing of AZD8233  (Study D7990C00002) will have 
been evaluated. Based on the results from these cohorts, the planned doses in the current study 
may be sl ightly adjusted if needed to achieve the intended PCSK9 and LDL -C reducti on. 
However, the highest dose will not exceed  (Days 1, 8, 29, and 57), which is the highest 
dose pl anned to be evaluated in Study  D7990C00002.
CCI
CCI
CCI
CCI
CCI
CCI
CCI
Clinical Study Protocol -2.[ADDRESS_942292] com pleted the study  if he/she has co mpleted all phases of 
the study  including the last visi t.
The end o f the study  is defined as the date of the last vi sit of the l ast parti cipant in the study . 
5. STUDY POPULATION
Prospective approv al of protocol  deviati ons to recrui tment and enro lment criteria, also known 
as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
Parti cipants are eligible to be included in the study only if all o f the following criteria apply:
Age
1Parti cipant m ust be 18to 75years of age, inclusive, at the time of signing the informed 
consent.
Type of Participant and Disease Characteristics
2Parti cipants who have a fast ing LDL -C ≥ 70 m g/dL (1.8 mm ol/L) but < 190 m g/dL 
(4.9mmo l/L) at screening (Visit 2).
3Have fast ing triglycerides < 400 mg/dL (< 4.52 mmo l/L) at screening (Visit 2).
4Shoul d be receiving moderate -or high-intensity statin therapy  (refer to Appendix H) as 
defined by [CONTACT_197006]/AHA guidelines on blood cholesterol management, or according to 
local guidelines.
5Shoul d be on stable medicat ion for ≥ [ADDRESS_942293] ion is 
for fenofibrate; if the participant is receiving feno fibrate, the therapy must be stable for at 
least 6 weeks prior to randomizat ion at a dose that is appropriate for the duration of the 
study  in the judgement of the In vestigator. Other fibrate therapy  (and derivat ives) are 
prohibited.
Weight
6Body  mass index between 19 and 40 kg/m2.
Sex
7 Male or f emale.
Contraceptive use by [CONTACT_694666] f or those parti cipat ing in clinical studies.
(a)Male parti cipants: 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 29of 95Males must be surgically sterile or using, in conjunction with their female 
partner, a highly effect ive method of contraception for the duration of the study 
(from the time they  sign consent) and for [ADDRESS_942294] ions, implants, or patches, IUDs, tubal 
ligation/occl usion, and vasectomy . A barrier m ethod is not ne cessary if the 
female partner is sterilized. Male study  parti cipants m ust not donate or bank 
sperm  during this same time period.
(b)Female participants:
Female participants must not be pregnant and must have a negat ive pregnancy 
test at screening and rando misation or be post-menopausal , must not be 
lactating, and must not be of childbearing potential. Women not of childbearing 
potenti al are defined as women who are either permanent ly sterilised 
(hysterectomy, bilateral oophorectomy, or bilateral salpi[INVESTIGATOR_1656]) , or who are 
postm enopausal. Wo men will  be considered postmenopausal if they  have been 
amenorrhoei c for 12 months prior to the planned date of rando misat ion without 
an alternative medical cause. The fo llowing age -specific requirements apply:
Women <[ADDRESS_942295] 
been amenorrhoeic for 12 months or more fo llowing cessat ion of 
exogenous hormonal treatment and FSH levels in the postmenopausal 
range.
Women ≥[ADDRESS_942296] sign and date both the consent forms for the main study 
and opti onal com ponent of the study . If a parti cipant decline to participate in the optional 
component of the study , there will be no penalt y or loss of benefi t to the parti cipant. T he 
participant will not be excluded fro m other aspects of the study  described in this protocol.
5.2 Exclusion Criteria 
Parti cipants are excl uded from  the study  if any of the fo llowing cri teria apply:
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 30of 95Medical Conditions
1Estimated glo merular filtration rate < 40 mL/min/1.73m2using the Chronic Kidney  
Disease -Epi[INVESTIGATOR_694644] 1.
2History  or presence of gastrointestinal, hepat ic or renal disease or any other condit ions 
known to interfere wit h absorption, distribut ion, metabolism, or exc retion of  drugs.
3Any uncontrolled or serious disease, or any  medical  (eg, known m ajor active infect ion or 
major haematological, renal, metabolic, gastrointestinal, or endocrine dysfunct ion) or 
surgi cal condi tion that, in the opi[INVESTIGATOR_3078] n of the Investigator, ma y either interfere wi th 
participat ion in the clinical study and/or put the participant at significant risk.
4Poorly controlled ty pe 2 di abetes m ellitus, defined as HbA1c > 10% at Visit 1.
5Acute i schaemic cardiovascular event in the last 12 months prior to r andomizat ion.
6Heart failure with [LOCATION_001] Heart Associat ion (NYHA) Class III -IV.
7Blood dy scrasias wit h increased risk of bleeding including idiopathic thrombocytopenic 
purpura and thrombotic thrombocy topeni c purpura or symptoms of increased risk of 
bleedin g (frequent bl eeding gums or nose bleeds).
8High-risk of bleeding diathesis as judged by [CONTACT_737].
9Malignancy  (except non -melano ma skin cancers, cervical in -situ carcinoma, breast ductal  
carcino ma in-situ, or Stage 1 prostate carcino ma) wi thin the l ast [ADDRESS_942297] asma apheresis within 12 months prior to randomizat ion.
12Uncontrolled hypertensio n defined as average supi[INVESTIGATOR_152358] > 160 mmHg or DBP > [ADDRESS_942298] < 50 bpm or > 100 bpm at Visit 1 or Visit 3.
14Any laboratory  values wit h the fo llowing deviat ions at Screening Visit 1; test may be 
repeated at the discret ion of the Investigator if abnormal:
(a)Any posi tive result on screening for hepatit is B, hepatit is C or HIV.
(b)ALT > 1.5 × ULN.
(c)AST > 1.5 × ULN.
(d)TBL > ULN
(e)ALP > 1.5 ×ULN
(f)WBC < LLN.
(g)Haem oglobin < 12 g/dL in m en or < 11 g/dL in women
(h)Platelet coun t ≤ LLN.
(i)aPTT > ULN and PT > ULN.
(j)UACR > 11.3 mg/mmo l (100 mg/g).
(k)UPCR > 300 mg/g
Clinical Study Protocol -2.[ADDRESS_942299] igator.
16QTcF > 470 ms; high degree atrioventricular -block grade II -III and sinus node 
dysfunct ion with significant sinus pause untreated with pacemaker; and cardiac 
tachy arrhy thmias.
17Known or suspected history  of drug abuse as judged by  [CONTACT_24342].
18History  of alcohol  abuse or excessive intake of alcohol as judged by [CONTACT_24342].
19Mipomersen, or l omitapi[INVESTIGATOR_694645] 12 months prior to randomizat ion.
20Previous administration of AZD8233/AZD6615 or other PCSK9 inhibit ion treatment 
(approved or invest igational).
21History  of severe allergy /hypersensi tivity or ongoing clinically important 
allergy/hypersensit ivity, as j udged by  [CONTACT_694667] a similar chemical structure or galactosamine -conjugated ASOs.
22Any clinically  important illness, m edical/surgical procedure or traum a within 4weeks o f 
the first administration o f study  interventi on. History  or evi dence of any  other clinically 
significant disorder (eg, cognit ive impairment), condit ion, or di sease other than those 
outlined above that, in the opi[INVESTIGATOR_3078] n of the Invest igator or [COMPANY_008] physician, if 
consulted, may  com promise the abilit y of the participant to give written informed 
consent, would pose a risk to participant safet y, or interfere wit h the study  evaluat ion, 
procedures, or completion.
Prior/Concurrent Clini cal Study Experience
23Parti cipation in another clinical study  with a study  intervent ion administered in the last [ADDRESS_942300]. 
24Receive d another new chemical ent ity (defined as a com pound which has not been 
approved for market ing) within [ADDRESS_942301] igatio nal devices during the course of the 
study .
Other Exclusions
26Involvement in the planning and/or conduct of the study (applies to both [COMPANY_008] 
staff and/or st aff at the study site or their close relatives).
27Judgement by  [CONTACT_694668], restrict ions and requirements. 
28As judged by  [CONTACT_24342], any  evidence of disease condit ions that, in the 
Invest igator’s opi[INVESTIGATOR_3078] n, makes i t undesirable for the participant to participate in the trial.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 32of 9529Previous enrolment or randomisat ion in the present study . Individuals who do not meet 
the criteria for par ticipat ion in this study  (screen failure) m ay be rescreened. At the 
Invest igator’s discret ion, participants may be rescreened a further two times during the 
recrui tment peri od.
30Parti cipants who cannot communicate reliably wit h the Invest igator.
31Vulnerable participants, eg, kept i n detent ion, protected adults under guardianship, 
trusteeship, or committed to an inst itution by [CONTACT_694669].
32Plasma donat ion within 1 m onth of the visit at the clinic or any  blood donati on/bl ood l oss 
> 500 mL duri ng the 3 months prior to screening visit.
Optional Genetic Sampling
Exclusio n from this genet ic research may be for any o f the excl usion criteria specified for the 
main study  or any  of the fo llowing:
33Previous allogeneic bone marrow transplant.
34Non-leukocyte depleted whole blood transfusio n wit hin [ADDRESS_942302] ivities or increase the intensit y of 
their usual  physical  training from  5 days pri or to rando mizat ion unt il the end of the study .
5.3.4 Reproductive restrictio ns
Women of Non -Child Bearing Potential
Women of non -child bearing potential are defined as female participants who are permanently 
surgically sterilized or postmenopausal (see inclusion criteria, Section 5.1).
Clinical Study Protocol -2.[ADDRESS_942303] on the development of the 
foetus in humans. Therefore, it is important that women of child bearing potential, who are the 
partners of male participants, do not beco me pregnant during the study and for a total period 
of 3months after the male participant has attended the Final Fo llow-Up Visit.
As a precaution, all male participants should avoid fathering a child by [CONTACT_694670] (together with their female partner/spouse) a highly effective contraception form 
of birth control  in combination wit h a barrier method, starting fro m the time of study  
intervent ion administration unt il 3months after the F inal Follow -Up visi t. Acceptable 
methods of prevent ing pregnancy include birth control pi[INVESTIGATOR_3353], inject ions, implants, or patches, 
IUDs, tubal ligat ion/occl usion, and vasectomy .
Male parti cipants who have been sterilized are required to use 1 barrier method o f 
contraception (condom) fro m the time of study  intervent ion administration until after the Final 
Follow-Up Visit. A  barri er method is not necessary if the female partner is sterilized.
Sperm Donation
Male parti cipants should not donate sperm  for the durat ion of the study  and f or at l east 
3months after the study  Final Foll ow-up Visit.
Pregnancy
Parti cipants will be instructed that if they  or thei r partner becomes pregnant during the study  
this shoul d be reported to the Investigator . The Investigator should also be notified of 
pregnancy occurring during the study  but confirmed after completion o f the study . In the event 
that a participant ’s partner is subsequently found to be pregnant after the participant is 
included in the study , then consent will be sough t from  the partner (via the participant ’s 
request that their partner contact [CONTACT_4145]) and, if granted, any  pregnancy  will be 
followed, and the status of mother and/or child will be reported to the Sponsor after delivery .
5.3.5 Blood donation
Parti cipants shoul d refrain fro m blood donation throughout the study , including the follow -up 
period.
5.4 Screen Failures
Screen failures are defined as part icipants who consent to participate in the clinical study  but 
are not subsequent ly rando mized to study  interventio n.A minimal set of screen failure 
inform ation is required to ensure transparent reporting of screen failure participants to meet 
the Consolidated Standards of Reporting Trials (CONSOR T) publishing requirements and to 
respond to queries from regulatory  autho rities. Minimal information includes demography , 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 34of 95screen failure details, eligibilit y criteria, and any  SAE.
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay be 
rescreened. At the Invest igator ’s discret ion, parti cipants m ay be rescreened a further two times 
during the recruit ment period. Rescreened parti cipants shoul d be assigned the same part icipant 
number as per their init ial screening visit.
6. STUDY INTERVENTION 
Study  intervent ion is defined as any invest igational intervent ion(s), m arketed product(s), 
placebo, or m edical device(s) intended to be administered to a study  parti cipant according to 
the study  protocol .
6.1 Study Intervention(s) Administered
6.1.[ADDRESS_942304] ion.In case of a change of the planned 
doses (as described in Sect ion 4.3), the invest igational product strength/concentrations may be 
used for other cohorts than prese nted in T able 4, in order to minimize inject ion volume.
Table 4 Investigational Pr oducts
ARM Name [CONTACT_133075] 1 Cohort 2 Cohort 3 Cohort 4
Intervention Name [CONTACT_99213]8233 AZD8233 AZD8233 Placebo to 
match 
AZD8233
Dose Formulation AZD8233 solution for injection Matching 
placebo 
solution for
injection
Strength/Concentrations Matching 
placebo 
solution for
injection
Dose Matching 
placebo 
solution for
injection
Regimen AZD8233/Placebo Days 1, 8, 29, and 57
Route of Administration Subcutaneous injection 
CCI
CCI
CCI
CCI
CCI
CCI
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 35of 95Table 4 Investigational Pr oducts
Treat ment Administration 
GuidelinesSubcutaneous abdominal region injection is the preferred region; 
avoid a 5 cm radius around umbilicus. Other regions might be used if 
needed, as decided by [CONTACT_3433] e investigator (thigh or buttock). Slow 
injection of study intervention using gentle pressure (at least 5 
seconds duration is recommended) and rotation of injection sites. 
The anatomical location of each injection site should be documented 
in the eCRF.
Specific device for drug 
administrationSyringes for injection to be provided by [CONTACT_694671]8233 
IMP and NIMP IMP 
Sourcing Provided centrally by [CONTACT_694672]. Each vial will be 
packed in a separate carton. Each vial and carton will be 
labelled as required per country requirement
Special Handling Requirements Requir ements will be provided in a separate document
Availability of IMP Will be shipped when approvals are in place
6.2 Preparation/Handling/Storage/Accountability of Interventions
1The Investigator or designee must confirm appropriate temperature condit ions have been 
maintained during transit for all study  intervent ion received and any discrepancies are 
reported and resolved before use of the study  intervent ion.
2Only participants enro lled in the study  may receive study  intervent ion and only authorised 
site staff may supply or administer study  intervent ion. All study  intervent ion must be 
stored in a secure, environmentally controlled, and monitored (manual or automated) area 
in accordance wit h the labelled storage condit ions with access limited to the Invest igator 
and authorised site staff.
3The Investigator, inst itution, or the head of the medical inst itution (where applicable) is 
responsible for study  interventi on accountabilit y, reconciliat ion, and record maintenance 
(ie, recei pt, reconciliat ion, and final disposit ion records).
4Further gui dance and information for the final disposit ion ofunused study  interventi ons 
are provided in the Study  Drug Packaging Agreement .
6.3 Measures to Minimise Bias: Randomization and Blinding 
All participants will be centrally assigned to randomized study  intervent ion using a R TSM 
Clinical Study Protocol -2.[ADDRESS_942305] ions and/or the 
log in informat ion & directions for the R TSM will be provided to each site.
To simplify supply of study drug, randomizat ion will be stratified based on the region in 
which the site is locate d. This will achieve greater balance within each region co mpared to 
simple rando mizat ion. Currently , two regi ons are planned: Europe and North America.
Study  intervent ion will be dispensed at the study  visits summarized in SoA.
The R TSM will  provide to the Investigator(s) or pharmacists the kit ident ificat ion number to 
be allocated to the participant at the dispensing visit. Routines for this will be described in the 
RTSM user manual that will be provided to each centre. 
The rando misat ion code should not b e broken except in medical emergencies when the 
appropriate management of the participant requires knowledge of the treatment randomisation. 
The Investigator documents and reports the action to [COMPANY_008], without revealing the 
treatm ent given to particip ant to the [COMPANY_008] staff. [COMPANY_008] retains the right to break 
the code for SAEs that are unexpected and are suspected to be causally related to an 
investigat ional product and that potentially  require expedi ted reporting to regul atory  
authori ties. Ra ndomisat ion codes will not be broken for the planned analyses of data until all 
decisio ns on the evaluabilit y of the data from  each individual part icipant have been made and 
docum ented.
The R TSM will  be programmed wit h blind -breaking instructions. In case of an emergency , in 
which the knowledge of the specific blinded study  treatm ent will affect the immediate 
management of the participant ’s condi tion (eg, antidote available), the Invest igator has the 
sole responsibilit y for determining if unblinding of a pa rticipants ’ interventi on assignment is 
warranted. Participant safet y must al ways be the first considerat ion in making such a 
determinat ion. If a participant ’s intervent ion assignment is unblinded, the sponsor must be 
notified wit hin [ADDRESS_942306] ion site, will be 
recorded in the source documents and recorded in the eCRF . The dose of study  interventi on 
and study  parti cipant i dentification will be confirmed at the time of dosing by a member of the 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 37of 95study  site staf f other than the person administering the study  interventi on.
Dosing visit s may be undertaken as ho me visits by [CONTACT_548845] . If parti cipants are dosed at home, 
they will receive study  intervent ion directly from site staf fThe dose administered at home will 
be recorded in the source documents. 
6.5 Concomitant Therapy
Any medicat ion (including over -the-coun ter or prescript ion medicines, vitamins, and/or herbal 
supplements) or vaccine that the participant is receiving at the time of enrolment or receives 
during the study  must be recorded along wit h:
Reason for use
Dates of administration including start and end dates
Dosage information including dose and frequency
Invest igators may prescribe concomitant medicat ions or treatments deem ed necessary to 
provi de adequate care for participants except for those medicat ions excluded below or listed in 
the exclusio n criteria. Specifically , partici pants shoul d receive full supportive care during the 
study  as deemed appropriate, and in accord ance with local guidelines.
The fo llowing m edical restri ctions apply:
Medicat ions / therapi[INVESTIGATOR_694646] m use for the 
durati on of  the parti cipant’s involvement in the study . 
All study  parti cipants shoul d be rece iving moderate -or high-intensity statin therapy  as 
defined by [CONTACT_197006]/AHA guidelines on blood cholesterol management, or according to 
local guidelines.
Parti cipants shoul d be on stabl e medicat ion for ≥ 3 months prior to screening with no 
planned medicat ionor dose change during study  parti cipat ion. The except ion to thi s 
restri ction is for fenofibrate; if the participant is receiving feno fibrate, the therapy must be 
stable for at least 6 weeks prior to randomization at a dose that is appropriate for the 
duration of  the study  in the j udgement of the Investigator. Other fibrate therapy  (and 
derivat ives) are prohibited. 
Parti cipants shoul d not be on any anti- platelet therapy  other than l ow-dose aspi [INVESTIGATOR_248] 
(≤ 100 mg/day). 
Parti cipants m ust abstain from  making dose changes and taking new prescript ion or non -
prescri ption drugs without consultat ion of the Investigator (including vitamins and dietary  
or herbal supplements) within 7 days (or 14 day s if the drug is a potential enzyme 
inducer) or 5 half -lives (whichever i s longer) before the start of study  interventi on (Visi t 
3) until co mpletion of the fo llow-up visit s.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 38of 95Paracetamo l/acetaminophen , at doses of 2g/day , is permi tted f or use any t ime during 
the study . Other concomitant medicat ion may be considered on a case -by-case basis by 
[CONTACT_694673] .
The Medical Monitor should be contact[CONTACT_694674] .
6.5.[ADDRESS_942307] be 
recorded including:
Nam e of medicat ion;
Reason for use / change;
Dates of administration including start and end dates;
And dosage informat ion including dose and frequency.
6.[ADDRESS_942308] anned intervent ion following the end of the study .
7. DISCONTINUATION OF S TUDY INTERVENTION AN D 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL
7.[ADDRESS_942309] ion:
Confirmed platelet count < 75,000/µL (see Appendix Fin case of uninterpretable platelet 
count) 
Hy’s Law defined as ‘an increase in AST or ALT ≥ 3 ×ULN and TBL ≥ 2 ×ULN’, 
where no other reason, other than the study  treatment, can be found to explain the 
combinat ion of increases
ALT or AST > 8 × ULN 
ALT or AST > 5 × ULN for > 2 weeks 
ALT or AST > 3 × ULN and TBL > [ADDRESS_942310] or INR > 1.5 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 39of 95ALT or AST > 3 × ULN with the appearance of fatigue, nausea, vo miting, right upper 
quadrant pain or tenderne ss, fever, rash, and/or eosinophilia ( > 5 %)
Confirmed increase in serum creatinine o f 0.3 m g/dL f rom baseline
Confirmed 25% decline in eGFR fro m baseline
Confirmed new -onset haem aturia, albuminuria (UACR ≥ 300 m g/g), or proteinuria 
(UPCR ≥ 500 mg/g)
Hypersensi tivity react ion CTCAE grade 3 or higher
Parti cipants may  be discont inued fro m study  intervent ion in the fo llowing si tuations:
Parti cipant decisi on. The parti cipant i s at any  time free to di scont inue treatment, without 
prejudice to further treatment
Adverse Event
Severe non -compliance wi th the CSP
If a participant discont inues study  treatm ent, he or she will be encouraged to return to the 
study  site for the EDV (see T able 1). Where possible, the EDV should be at the next visit 
according to the origin al visi t schedule, unless consent is wit hdrawn from further study  
participat ion. To secure recommended safety  follow-up, parti cipants attending an EDV should 
also be asked to con tinue to return for their originally  scheduled visi ts for a total  of three 
months, unless they  are unable to or unwilling to return. Note that discont inuat ion from study  
intervent ion is NOT the same thing as a withdrawal fro m the study .
See the SoA  for data to be collected at the time o f intervent ion discontinuation and fo llow-up 
and for any  further evaluat ions that need to be completed.
7.2 Participant Withdrawal from the Study 
A participant may withdraw fro m the study  at any  time at hi s/her own request or may be 
withdrawn at any  time at the di screti on of  the Investi gator for safet y, behavi oural , 
compliance, or administrative reasons. This is expected to be unco mmo n.
A participant who considers wit hdrawing fro m the study  must be informed by  [CONTACT_694675]-up opti ons (eg, telephone contact, a con tact wi th a 
relative or treating physician, or information fro m medical records).
At the time of withdrawal fro m the study , if possible, an EDV should be conducted, as 
shown in the SoA. See SoA for data to be collected at the time o f study  withdrawal  and 
follow-up and for a ny further evaluat ions that need to be completed.
The parti cipant will discont inue the study  interventio n and be wit hdrawn from the 
study  at that time.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 40of 95If the participant withdraws consent for disclosure of future informat ion, the sponsor may  
retain and co ntinue to use any data collected before such a withdrawal o f consent.
If a participant withdraws fro m the study , it shoul d be confirmed if he/she st ill agrees for 
exist ing samples to be used in line with the original consent. If he/she requests withdrawal 
of consent for use of samples, destruction of any samples taken and not tested should be 
carried in line wit h what was stated in the informed consent and local regulat ion. The 
Invest igator must document the decisio n on use of exist ing samples in the site s tudy 
records and inform the Global Study  Team /CRA.
7.[ADDRESS_942311] be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact [CONTACT_394096] o f maintaining the assi gned visi t 
schedule and ascertain whether or not the participant wishes to and/or should continue in 
the study .
Before a participant is deemed lost to fo llow up, the Invest igator or designee must make 
every effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, 
if necessary , a certified l etter to the parti cipant’s last known mailing address or local 
equivalent m ethods). These contact [CONTACT_13140]’s 
medical record.
Shoul d the participant c ontinue to be unreachable, he/she will be considered to have 
withdrawn from  the study . 
Site personnel, or an independent third party , will  attem pt to collect the vital status of the 
participant wi thin legal  and ethical boundaries for all participants rand omised, including 
those who di d not get invest igational product. Public sources may be searched for vital 
status information. If vital status is determined as deceased, this will be documented, and 
the participant will not be considered lost to fo llow-up. Sponsor personnel will not be 
involved in any attempts to collect vital status info rmation.
Discontinuati on of  specific sites or of the study  as a who le are handled as part of Appendix A.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 41of 958. STUDY ASSESSMENTS AN D PROCEDURES 
Study  procedures and their timing are summarised in the SoA. Protocol waivers or 
exempt ions are not allowed. Assessments scheduled at the same t ime may be initiated 
based on the seque nce below
1ECG
2Vital signs (SBP and diastolic blood pressure [DBP]), pulse rate, and temperature, if 
appropriate)
3PK and PD blood sampling
4Dose administration
Pre-dose assessments may be performed up to 60 minutes prior to dosing.
Immediate safet y concerns shoul d be discussed wit h the sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
study  interventi on.
Adherence to the study  design requi rements, including those specified in the SoA, is 
essent ial and requi red for study  conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that potential 
participants m eet all eligibilit y criteria. The Invest igator will maint ain a screening log to 
record details o f all participants screened and to confirm eligibilit y or record reasons for 
screening failure, as applicable.
Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of the ICF may be utilised for screening or baseline
purposes provided the procedures met the protocol -specified criteria and were performed 
within the t ime frame defined in the SoA.
The study  is divided into one treatment period and one safet y follow up peri od. The treatment 
period starts after the screen ing visits (V isit 1: Day -42 to Day -1; Visit 2: Day -7 to Day  -1). 
During Visit 1, the participants will be checked for eligibilit y and enro lled to the study . 
Addit ional samples will be co llected on V isit 2. Approximately 108 participants will be 
rando mized at V isit 3 (Day 1) in a 1:1:1:[ADDRESS_942312] ions of AZD8233 (planned doses 
, , and ) or m atching placebo. AZD8233 or placebo will be administered SC 
on Visit 3, 4, 6, and 8. The participants will be treated for 84 days (12 weeks) wi th AZD8233 
or placebo. Thereafter, the participants will continue in a safet y follow up peri od for 12 weeks; 
the final fo llow up visit will be performed on W eek 24 ([ADDRESS_942313] dose of AZD8233 
or placebo).
General description of visits:
Visit 1 (enr olment) and V isit 2: At Visit 1 (Day  -42 to Day  -1), parti cipants will be asked to 
CCI
CCI
CCI
Clinical Study Protocol -2.[ADDRESS_942314] ion. Enrolment will be performed in R TSM. V isit 2 (Day  -7 to Day -1) will include an 
blood sam ple collect ion for LDL -C, PCSK9, and triglycerides. 
Visit 3 (randomization): Visit 3 (Day  1) shoul d be perform ed wi thin [ADDRESS_942315] 8 hours overnight, prior to the vis it; participants are 
permitted to drink water during this period until [ADDRESS_942316] be verified by [CONTACT_694676] n/exclusio n criteria. 
A complete physical examinat ion must be perf ormed. Blood and urine samples to be obtained 
prior to administration of study  intervent ion in fasted state. ADA  sample will be obtained pre -
dose. V ital signs and ECG to be checked. If the participant fulfils all inclusio n criteria and 
none of the exclusio n criteria, they  will be rando mized in R TSM and study  intervent ion will 
be administered as SC inject ion. 
Visit 4, 6, and 8: Visit 4(Day  8 ± 1 day ), Visit 6 (Day 29 ± 2 day s), and V isit 8 
(Day 57 ± 2 days) are pl anned as clinical visit s but may  also be un dertaken at the participant's 
home or any  other appropri ate locati on if deemed applicable, by [CONTACT_6624], following 
consultation wit h the sponsor . At V isits 4, 6, and 8, study  intervent ion will be administered as 
SC inject ions. Parti cipants are required to fast for at l east [ADDRESS_942317] be done pre -dose. An abbreviated physical examinat ion is required at the 
visits as well as ECG and vital signs examinat ion. 
Visit 5, 7, and 9: ForVisit 5 (Da y 22 ± 2 day s), V isit 7 (Day 43 ± 2 day s), and V isit 9 
(Day 71 ± 2 day s), are planned as clinical or home visit s that ma y be undertaken at the 
participant's ho me or any other appropriate location by [CONTACT_694677] . PK sampling to be performed at V isits 7 and 9. An abbreviated physical 
examinat ion is required at the visits. V ital signs, blood and urine samples to be taken at the 
visits. 
Safety follow up visits (V isit 10 -15): ECG m ust be perform ed at V isit 10 (Day  85 ± 2 days), 
Visit 11 (Day  99 ± 2 day s), V isit 13 (Day 127 ± 2 days) and V isit 15 (Day  155 ± 2 days). At all 
safet y follow up visi ts, an abbreviated physical examinat ion is required, and vital signs, blood, 
and urine samples are to be checked. PK and ADA  sampli ng are to be performed at V isit 10 
(Day  85 ± 2 day s), V isit 12 (Day  113 ± 2 day s) and V isit14 (Day  141 ± 2 days). V isit 11, 13, 
and 15 are listed as ho me visit s in the SoA. Those visit s may be undertaken at the participant's 
Clinical Study Prot ocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 43of 95home or any  other appropri ate location. Other vi sits currently not designated as “home vis its” 
may also be undertaken at the participant's ho me or any other appropriate location if deemed 
applicable, fo llowing consultat ion with the sponsor . 
Early Discontinuation V isit:The EDV may take pl ace any time during the study , in case a 
participant discont inues study treatment prior to V isit 8 (where last dose of study treatment is 
administered). The same assessments as during the final fo llow up visit will be performed. See 
Secti on 7.1.
Final follow up visit: The final fo llow up visit will be performed on Day  169 (± 2 day s). PK 
and ADA  sampling to be perform ed. A  com plete physical  examinat ion must be performed on 
the visit, and body  weight, BMI, vi tal signs, and ECG to be checked. Blood and urine 
sampling to be obtained.
The m aximum  blood vol ume to be drawn fro m each subject should not exceed [ADDRESS_942318] ion 8.5.3 for assessments which will be used for prima ry and key  secondary  
efficacy analyses.
8.2 Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoA.
8.2.1 Physical Exa minations
A co mplete physical examinat ion will include assessments of the fo llowing; general  
appearance, respi[INVESTIGATOR_83731],cardi ovascular, abdom en, skin, head and neck (including ears, 
eyes, nose and throat), lymph nodes, thy roid, muscul oskeletal  (including spi[INVESTIGATOR_499460]), and neurological systems. 
An abbreviated physical examination will include, at a minimum, a ssessments of the skin, 
lungs, cardiovascular system, and abdo men (liver and spleen). During the ho me vis its, the 
abbreviated physical exam can be conducted via a symptom led assessment.
Body  weight shoul d be measured in light indoor clothes without shoes, after a pri or visit 
to the bathroom.
Physical examinat ion will be performed at the time points specified in the SoA. BMI will be 
calculated at the time points specified in the SoA.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 44of 958.2.2 Vital Signs
Vital signs (blood pressure, pulse and temperature) will be p erformed at the time points 
specified in the SoA.
Blood pressure and pulse measurements will be assessed in supi[INVESTIGATOR_694647] a 
completely autom ated device. Manual techniques will be used only  if an autom ated 
device is not available.
BP and pulse measur ements shoul d be preceded by [CONTACT_2669] [ADDRESS_942319] for the 
participant in a quiet setting without distractions (eg, televisio n, cell  phones).
Vital signs (to be taken before blood collect ion for laboratory  tests) will  consist of 1 pulse and 
3 BP meas urements ([ADDRESS_942320] 
1minute). The average of the [ADDRESS_942321] 10 
minutes. The fo llowing parameters or time intervals will be recorded for each ECG: RR, PR, 
QRS, QT , QTcF, and HR.
The same recorder should be used for each participant at each time point, if possible.
From  the ECG data, the fo llowing parameters will be derived: 
-QTcF will be calculated as QT cF=QT*RR^ -1/3, where the QT interval is in milliseconds and 
the RR interval is in seconds.
-Heart rate will be calculated, based on the RR interval as HR=60/RR interval, where the RR 
interval  is in seconds.
Calculation o f derived parameters will be performed after averaging of QT and RR data. 
The ECG data will be averaged on an individual basis before performing the derivations 
above and pri or to cal culat ion of any  changes from baseline or descript ive statistics. For each 
participant, i t will  be done as fo llows: the m ean value of all measurements will be taken 
provi ded that at least 2 measurements are present (and at least 3 consecut ive beats were 
analyzable in each ECG) or else, the averaged value at the corresponding target time point will 
be set to missing. 
ECG resul ts will be listed by [CONTACT_694678]8233 for each participant and 
time point and will include all individual and averaged values of PR, RR, QRS, QT interval, 
and the derived values o f QTcF and HR (RR). All averaged and derived parameters will have 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 45of 95changes fro m baseline derived and presented. 
Descript ive statistics will be presented by [CONTACT_694678]8233, time point 
for averaged values and changes from baseline o f averaged values of PR, RR, QRS, QT ; 
derived values and changes fro m baseline for QT cF and HR will also be included. The 
baseline for the dECG measurements will be the pre- dose assessment on Day  1. 
Outliers with respect to QT cF will also be tabulated for the following categories: 
Absolute value > 450 ms and ≤ 480 ms.
Absolute value > 480 ms and ≤ 500 ms.
Absolute value > 500 ms.
Increase from baseline > 30 ms and ≤ 60 ms.
Increase from b aseline > 60 m s.
The Investigator (or qualified designee) will make an overall evaluat ion of the ECG as normal 
or abnorm al. If abnormal , it will  be decided whether the abnormalit y is clinically  significant 
or not clinically  significant, and the reason for the abnorm ality will be recorded on the eCRF .
Abnorm al values shall  not be recorded as AEs unless deemed clinically significant. The 
printout of the ECG is to be signed, dated, and filed in the ISF along wit h a signed and dated 
copy  (if the printouts are n ot on archive -qualit y paper).
The Investigator may  perform addi tional 12-lead ECG assessments in case o f any abnormal 
findings or if considered required by  [CONTACT_694679] y reason. These 
assessments should be entered as an unscheduled assessment.
8.2.[ADDRESS_942322] ion and results (values, unit s and reference ranges) will 
be recorded on the appropriate eCRF .
All laboratory  variables will be analysed at Covance central lab. Samples will b e collected, 
handled, labelled, stored and shipped as detailed in the laboratory  manual. 
The fo llowing laboratory  variables will be measured.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 46of 95Table 5 Laboratory safety variables 
Haematology/Haemostasis (whole blood) Clinical Chemistry (serum or plasma)
White blood cell (WBC) count Sodium
Red blood cell (RBC) count Potassium
Haemoglobin (Hb) Blood urea nitrogen (BUN)
Haematocrit (HCT) Creatinine
Mean -corpuscular volume (MCV) Calcium
Mean corpuscular haemoglobin concentration 
(MCHC)Phosphate
Neutrophils absolute count Creatine kinase (CK)
Lymphocy tes absolute count Direct bilirubin
Monocytes absolute count Alkaline phosphatase (ALP)
Eosinophils absolute count Alanine aminotransferase (ALT)
Basophils absolute count Aspartate aminotransferase (AST)
Platelets absolute count Gamma glutamyl transpeptidase (GGT)
Reticulocytes absolute count Total bilirubin (TBL)
Glutamate dehydrogenase (GLDH)
Urinalysis (dipstick) Bicarbonate
Urinalysis (positive dipstick) Uric acid
pH FSH (women only)
Specific gravity LH (women only)
Glucose
Blood Coagulation
Colour Prothrombin time 
Protein Activated partial thrombin time (aPTT)
Clarity /Appearance International normalized ratio (INR)
Nitrites
Ketones Urine renal safety biomarkers
Leukocytes Albumin
Microscopic analysis (if positive for blood, nitrites or 
protein)Total protein
Urobilinogen Creatinine
Urine protein to creatinine ratio (UPCR)
Other Laboratory Assessments Urine albumin to creatinine ratio (UACR)
Complement activation panel (C3a, Bb, C5a) Estimated glomerular filtration rate (eGFR; by 
[CONTACT_9289] -EPI [INVESTIGATOR_14420])
High -sensitivity C -reactive protein (hs -CRP)
Clinical Study Protocol -2.[ADDRESS_942323] orALT ≥ 3 × ULN together with TBL  ≥ 2 × ULN 
please refer to Appendix E(Actions required in cases of increases in liver biochemistry  and 
evaluat ion of Hy ’s Law) for further instructions. 
8.2.5 Other Screening Assessments
Other screening assessments referred to in the SoA ( Table 1) are shown in 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 48of 95Table 6 Other  Screening Assessments
.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 49of 95Table 6 Other  Screening Assessments
HbA1c
Viral Serology Screen
Hum an immunodeficiency virus (HIV) I Hepatitis B surface antigen (HBsAg)
Hepatitis B virus DNA (HBV DNA)
HIV II Hepatitis C virus antibody
Hepatitis C virus RNA (HCV RNA)
8.2.[ADDRESS_942324] ion site reactions (ISR) should be reported using standard AE collect ion criteria. Details 
regarding the ISRs will be collected in a specific eCRF page.
8.[ADDRESS_942325] ion
The definit ions of an AE or SAE can be found in Appendix B.
Adverse events will be reported by  [CONTACT_17071] (or, when appropriate, by  a caregiver, 
surrogate, or the participant's legally authorised representative). 
The Investigator and any designees are responsible for detecting, document ing, and recording 
events that meet the definit ion of an AE.
8.3.[ADDRESS_942326] dose throughout the treatment period and 
including the follow -up peri od.
Serious adverse events will be recorded from the time of signing of the ICF .
If the Investigator becomes aware of an SAE with a suspected causal relat ionship to the study  
intervent ion that occurs after the end of the clinical s tudy in a parti cipant treated by  [CONTACT_531427], the Investigator shall, without undue delay , report the SAE to the sponsor .
8.3.2 Follow- up of AEs and SAEs
Any AEs that are unreso lved at the participant ’s last AE assessment in the study are fo llowed 
up by  [CONTACT_694680] l ong as m edically indicated, but without further recording in the 
eCRF . [COMPANY_008] retains the right to request additional information for any  parti cipant wi th 
ongoing AE(s)/SAE(s) at the end of the study , if judged necessary .
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 50of 95Adverse event variables
The fo llowing variables will be collected for each AE:
AE (verbat im)
The date and time when the AE started and stopped
Maximum intensit y 
Whether the AE is serious or not
Invest igator causalit y rating against the study  intervent ion (yes or no)
Action taken with regard to the study  intervent ion
AE caused participant’s withdrawal fro m study  (yes or no)
Outcom e
In addit ion, the fo llowing vari ables will be collected for SAEs:
Date AE m et cri teria for seri ous AE
Date Invest igator became aware of ser ious AE
AE is seri ous due to
Date of hospi[INVESTIGATOR_72913]
Date of discharge
Probable cause of death
Date of death
Autopsy  performed
Causalit y assessment in relat ion to Study  procedure(s)
Causalit y assessment to other medicat ion
8.3.3 Causality Collection
The Investi gator shoul d assess causal relat ionship between the study  intervent ion and each 
AE, and answer ‘yes’ or ‘no’ to the questi on ‘Do you consider that there is a reasonable 
possibilit y that the event may  have been caused by [CONTACT_7198]? ’
For SAEs, causal relat ionship should also be assessed for other medicat ion and study  
procedures. Note that for SAEs that could be associated with any study  procedure the causal 
relationship is implied as ‘yes’.
A guide to the interpretation of the causali ty question is found in Appendix Bto the CSP .
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 51of 958.3.4 Adverse Events Based on Signs and Symptoms
All AEs spontaneously reported by [CONTACT_694681]: ‘Have y ou had any heal th probl ems since the previous visit/y ou were 
last asked? ’, or revealed by [CONTACT_122614] . When 
collect ing AEs, the recording of d iagnoses is preferred (when possible) to recording a list of 
signs and symptoms. However, if a diagnosis is known and there are other signs or symptoms 
that are not generally part of the diagnosis, the diagnosis and each sign or symptom will be 
recorded se parately
.
8.3.5 Adverse Events Based on Examinations and Tests 
The results from the CSP mandated laboratory tests and vital signs will be summarised in the 
CSR. 
Deteri oration as com pared to baseline in protocol -mandated l aboratory  values and vital signs 
shoul dtherefore only  be reported as AEs if they fulfil any o f the SAE cri teria, are the reason 
for discont inuat ion of treatment with the study  intervent ion or are considered to be clinically 
relevant as j udged by [CONTACT_737] (which may  include but not limi ted to consi derati on as 
to whether treatment or non -planned visits were required or other action was taken with the 
study  treatm ent, eg, dose adjust ment or drug interruption).
If deteri oration in a laboratory  value/vi tal sign i s associ ated wi th clinical s igns and symptoms, 
the sign or symptom  will be reported as an AE and the associated laboratory  resul t/vital sign 
will be considered as addit ional informat ion. Wherever possible the reporting Invest igator 
uses the clinical, rather than the laboratory  term  (eg, anaemia versus low haemoglo bin value). 
In the absence of clinical signs or symptoms, clinically relevant deteriorations in non -
mandated parameters should be reported as AE(s).
Deteri oration of  a laboratory  value, which is unequivocally due to disease progression, should 
not be reported as an AE/SAE (see also Section 8.3.7 ). 
Any new or a ggravated clinically relevant abnormal medical finding at a physical examinat ion 
as com pared wi th the baseline assessment will be reported as an AE unless unequivocally 
related to the disease under study .
8.3.6 Hy’s Law
Cases where a participant shows elevations in liver biochemistry  may requi re further 
evaluat ion and occurrences of AST or ALT ≥ 3 × ULN together with TBL  ≥ 2 × ULN may 
need to be reported as SAEs. Please refer to Appendix Efor further instructi on on cases of 
increases in liver biochemistry  and evaluat ion of Hy ’s Law .
Clinical Study Protocol -2.[ADDRESS_942327], or to the study  procedure(s). All SAEs will be recorded in the eCRF .
If any SAE occurs in the course of the study , then Investigators or other site personnel inform 
the appropriate [COMPANY_008] representatives within one day , ie, immediately but no later  than 
[ADDRESS_942328] igator or other study  site staf f report s an 
SAE to the appropriate [COMPANY_008] representative by  [CONTACT_756].
The [COMPANY_008] representative will advise the Investigator/study site staff how to proceed. 
Invest igators or other site personnel send relevant CRF modules by [CONTACT_6791] ( [PHONE_14458] -763-734) or 
email (AEMailbo [EMAIL_13285] )to [COMPANY_008] Pat ient Safet y Data 
Entry  Site, Tata Consultancy Services.
The reference document for definit ion of expectedness/listedness is the IB for the [COMPANY_008] 
drug. 
8.3.8 Pregnancy
All pregnancies and outcomes of pregnancy should be reported to [COMPANY_008] except for:
If the pregnancy  is discovered before the study  parti cipant has received any  study  
drug.
[IP_ADDRESS] Maternal Exposure
Women of childbea ring potenti al are not allowed to be included in this study . Shoul d a 
Clinical Study Protocol -2.[ADDRESS_942329] iveness of a contraceptive medicat ion. Congenital 
abnorm alities/birth defects and spontaneous miscarriages should be reported and handled as 
SAEs. Elective abortions wit hout compl ications should not be handled as AEs. The outcome 
of all pregnancies (spontaneous miscarriage, elect ive terminat ion, ectopic pregnancy , normal  
birth or congenital abnormalit y) shoul d be fo llowed up and docum ented even if the part icipant 
was discont inued f rom the study .
If any pregnancy  occurs, then the Invest igator or other site personnel informs the appropriate 
[COMPANY_008] representatives within [ADDRESS_942330] igator to ensure that all 
relevant informat ion is provided to the [COMPANY_008] Pati ent Safet y data entry  site wi thin 1 or 5 
calendar day s for SAEs (see Secti on 8.3.7 ) and within 30 days for all other pregnancies.
The same timelines apply when outcome informat ion is available.
The PREGREP module in the eCRF is used to report the pregnancy and the PREGOUT is 
used to report the outcom e of the pregnancy .
[IP_ADDRESS] Paternal Exposure
Male parti cipants shoul d refrain from  fathering a child during the study  and f or 3 m onths 
following the final fo llow-up visit (see also Section 5.3.4 ).
In case of pregnancy o f the partner of a male participants, the partner ’s pregnancy should be 
reported on the pregnancy form (consent fro m the partner m ust be obtained before the 
pregnancy form is completed) fo llowing the same timeframe and routing as described for any  
participant ’s pregnancy . Pregnancy of the participant's partner is not considered to be an AE. 
These pregnancies will also be fo llowed up, and the outcome of the pregnancy (spontaneous 
miscarri age, el ective termi nation, ectopic pregnancy , norm al birth or congenital abnormalit y) 
shoul d, if possible, be obtained and documented.
8.3.[ADDRESS_942331] igator to ensure that all 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 54of 95relevant informat ion is completed wi thin 1 (Init ial Fatal /Life -Threatening or follow up 
Fatal /Life -Threatening) or 5 (other serious init ial and fo llow up) cal endar days if there is an 
SAE associated with the medicat ion error (see Sectio n 8.3.7 ) and within [ADDRESS_942332] ice.
An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the 
relevant AE m odules in the eCRF and on the Overdose eCRF module.
An overdose without associated symptoms is only  reported on the Overdose eCRF 
module.
If an overdose on an [COMPANY_008] study drug occurs in the course of the study , then the 
Invest igator or other site personnel inform appropriate [COMPANY_008] representatives 
immediately , or no later  than [ADDRESS_942333] confident iality. For further details on Handling o f Hum an Bi ological 
Sample, see Appendix C.
Samples will  be stored for a m aximum  of 15 y ears fro m the date of the i ssue of the CSR in 
line with consent and local requirements, after which they will be destroyed/repatriated. 
Pharmacokinet ic samples will be disposed of after the Bioanalyt ical Report finalizat ion or 
six mo nths after issuance of the draft Bioanalyt ical Report (whichever is earlier), unless 
consented for future analyses. 
Pharmacokinet ic samples may be disposed o f or anonymised by [CONTACT_76435]. Addit ional 
analyses may be conducted on the anonymised, pooled, or individual PK samples to 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 55of 95further evaluate and validate the analyt ical method. Any results fro m such analyses 
may be reported separately fro m the CSR.
Remaining ADA sample aliquots will be retained at [COMPANY_008] or its designee for a 
maximum o f 15 years fo llowing issue of the CSR. Addit ional use includes but is not 
limited to further characterizat ion of any ADAs, confirmat ion and/or requalificat ion of 
the assay a s well  as addi tional assay  devel opment work. The results from future analysis 
will not be reported in the CSR.
8.5.[ADDRESS_942334] igator and the sponsor, eg, for safet y reasons. The timing of sampling 
may be altered during the course of the study  based on newly available data (eg, to ob tain data 
closer to the time of peak or trough matrix concentrations) to ensure appropriate monitoring. 
Plasma samples will be used to analyse the PK of AZD8233. Samples co llected for analyses 
of AZD8233 concentrati on m ay also be used to e valuate safet y or efficacy aspects related to 
concerns arising during or after the study .
Samples will  be collected, l abelled, stored, and shipped as detailed in the Laboratory  Manual.
[IP_ADDRESS] Determination of Drug Concentration
Samples for determination of drug c oncentration (AZD8233 full lengths ASOs) in plasma will 
be assayed at bioanalyt ical test si tes operated by  [CONTACT_39805] o f Ast raZeneca, using an 
appropriately  validated bi oanaly tical method. Full  details of the analy tical method used will be 
described in a separate bioanalyt ical report.
Placebo sam ples will not be analysed, unless there is a need to confirm that correct treatment 
has been given to study  partici pants.
Drug concentration informat ion that would unblind the study  will not be reported to 
investi gative sites or blinded personnel unt il the study has been unblinded.
Incurred sample reproducibilit y analysis or addit ional assay  devel opment/validati on work, if 
any, will  be perform ed al ongside the bioanalysis of the test samples. The results fro m the 
evaluat ion, if performed, will be reported in a separate Bioanalyt ical Report.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 56of 958.5.2 Immunogenicity Assessments 
Blood sam ples f or immunogenicit y assessments (ADA) will be collected according to the SoA 
(Table 1).
The presence or absence of ADAs will be determined in the plasma samples using a validated 
bioanalyt ical method. A tiered testing scheme will be emplo yed, wi th the first step being 
screening. Samples found posit ive in the screening step will be tested in the confirmatory  step. 
Samples confi rmed posi tive for ADA  in the confirmatory  step will undergo endpoint titre 
determinat ion. Full details of the analyt ical method and analyses performed will be described 
in a separate bioanalyt ical report.
ADA  samples may  also be further tested for characterisat ion of the ADA  response. Study  
resul ts may be reported independent ly to ADA  follow-up.
Samples will  be collected, l abelled, stored, and shipped as detailed in the Laboratory  Manual .
Parti cipants wi th treatm ent-emerging ADA -positive titres will be asked to return to provide 
another sample [ADDRESS_942335] dropped 97% from 
maximum.
8.5.3 Pharmacodynamics
[IP_ADDRESS] Collection of Samples
Blood sam ples will be collected for the assessment of PCSK9 and dyslipi[INVESTIGATOR_035] (
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 57of 95Table 7). Blood sam ples for the determinat ion of concentrations of PCSK9 and to evaluate the 
lipid parameters and lipoprotein profile (particle size and number) will be collected at the time 
points specified in the SoA  (Table1). 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 58of 95Table 7 Pharmacodynamic Laboratory Assessments
LDL -C PCSK9
Lipoprotein profile (particle size and number) Biomarkers analyses
Other lipid parameters including:
Total cholesterol HDL -C
non-HDL -C VLDL -C
ApoA1 ApoB
Lp(a) Triglycerides
Remna nts cholesterol
ApoA1 = apolipoprotein A1; ApoB = apolipoprotein B; HDL -C = high-density lipoprotein cholesterol; LDL -
C = low -density  lipoprotein cholesterol; Lp(a) = lipoprotein(a); PCSK9 = proprotein convertase 
subtilisin/kexin type -9; VLDL -C = very -low-density  lipoprotein cholesterol
For storage, re -use and destruction of pharmacodynamic samples see Secti on 8.5and 
Appendix C. 
8.6 Human  Biologic al Sample Biomarkers
8.6.1 Collection of Mandatory Samples for Biomarker Analysis
By [CONTACT_694682] , the parti cipant consents to take part in the mandatory  
research components of the study . 
Samples for bi omarker research are required and w ill be co llected fro m all part icipants in 
this study  as specified in the SoA. 
Collect ion and storage of blood (plasma) and urine samples for potential future 
exploratory  research aimed at exploring bio markers invo lved in PK, PD, safet y (including 
anti-platelet antibodi es) and tolerabilit y related to AZD8233 treatment or cardiometabolic 
diseases is part of this study .
Biomarkers to be taken:
Blood (pl asma) and urine sample analyses
Targeted and unbiased -omics approaches for evaluation of plasma and/or urin e 
samples for PD bio markers and bio marker research relat ive to safet y, tolerabilit y and 
PK profile related to AZD8233 treatment. 
8.[ADDRESS_942336] ion and shipment and destruction of these samples can be found in the 
Laboratory  Manual. 
For storage and destruction of genetic samples see Appendix D. 
8.8 Heal th Economics
Health Economics/Medical Resource Utilization and Healt h Economics parameters are not 
evaluated in this study .
9. STATISTICAL CONSIDER ATIONS
9.[ADDRESS_942337] 80 evaluable participants completed treatment up until and including visit 10 (week 12) . 
Any participant who receives at least one dose of study  intervent ion is considered evaluable 
and is included in the full analysis set. Participants are randomly assigned to study treatment 
cohorts in a ratio of 1:1:1:1.
The sample size of 20 participants per arm will provide 90% power in a two -sided t -test at 5% 
signifi cance l evel to detect a difference of 0.33 on the log scale; 0.[ADDRESS_942338] of the  
dose. The commo n SD for log -transformed LDL -C is assumed to be 0.3. 
CCI
CCI
CCI
CCI
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 60of 959.3 Populations for Analyses
The fo llowing popul ations are defined:
Table 8 Populations for  Analysis
Population/Analysis set Description
Enrolled All participants who sign the ICF.
Randomly assigned to study 
treatmentAll participants who were randomized. Participants will be analysed according 
to the treatment to which they were randomized.
Full analysis set All randomized participants who received at least [ADDRESS_942339] one dose of study treatment and who had 
evaluabl e PK data.
Any important protocol deviat ions from rando mized treatment will be listed and considered 
when interpreting the data. Important protocol deviations will be defined in the Non -
compliance Handling Plan (NHP).
9.[ADDRESS_942340] at a 5% significance level, if not 
explicit ly stated otherwise. The SAS® version 9.[ADDRESS_942341] ings will be appended to the final CS R. All tables, figures and 
listings will be presented in portable document format (PDF) without any manual edit ing, ie, 
they will appear unmodified as programmed by  [CONTACT_487455].
All results will be presented by  [CONTACT_694683]. Demographic and baseline characterist ics will be presented as fo llows; for 
continuous variables, the number of non -missing observat ions, m ean, SD, SEM, 95% CI of 
the mean, m edian, fi rst and thi rd qu artiles, minimum and maximum, will be presented; for 
categori cal variables: counts (n) and percentages (%) (where specified) will be presented. 
These summaries will be provided by [CONTACT_487454].
9.4.2 Efficacy 
The analysis and presenta tion of  efficacy and exploratory  endpoints will  be based on 
participants in the full analysis set. 
For selected efficacy variables, if not specified otherwise, a mixed model for repeated 
measures will be fit using log transformed data and results transfor med back to geometric 
mean ratios for the purpose of presentation and interpretation. The mixed model for repeated 
measures will include the relevant log transformed baseline bio marker value as a covariate. 
Time point (visit number), treatment, and the int eracti on between time point and treatment 
will be included as factors. The response variable will be change from baseline in log 
transformed bio marker value. The model will be fit with an unstructured covariance structure, 
and the Kenward- Roger correcti on applied to obtain the degrees of freedo m. Estimat ion of the 
treatm ent effect will be done for each visit after baseline. In case of issues when fitting the 
model to the data, a hi erarchical m odel fitting procedure will be described in the statist ical 
analy sis plan.
[IP_ADDRESS] Primary Endpoint(s)
The primary  efficacy endpo int is change fro m baseline in log -transform ed LDL -C at the end 
of Week [ADDRESS_942342] imated by [CONTACT_694684]. All 
treatm ent arm s will  be com pared wi th each other . 
For active treatment in the study , the geom etric m ean rati o will  be plotted over time.
[IP_ADDRESS] Secondary Endpoint(s)
Percentage change fro m baseline in LDL -C in the original  scale will be calculated for each 
participant and then co mpared between treatment groups using a mixed model for repea ted 
measures. 
Clinical Study Protocol -2.[ADDRESS_942343] ical analy sis plan.
For each treatment, the mean percentage change from baseline of LDL -C and PCSK9 levels 
will be plotted over time.
Pharmacokinetics
If data permit s a popul ation PK model will be developed, possibly wit h the support of PK data 
from studi es D7990C00001 and D7990C00002, using nonlinear mixed effects regression 
analysis in NONMEM. Furthermore, if data allows, the population PK model may be coupled 
with separate PD m odels for PCSK9 and LDL -C.
All PK/PD modelling will be described in a separate d ata analysis plan. Moreover, the results 
of any such modelling will be provided in a separate population PK/PD report (as an appendix 
to the CSR or as a stand -alone report).
Plasma concentration data of AZD8233 will also be summarized by [CONTACT_694685] t ime point in the CSR.
9.4.3 Safety
All safet y analyses will be performed on the Safety  analysis set. Safet y variables are AEs, vital 
signs, 12 -lead ECGs and laboratory  assessments. 
Safety variables will be summarised by [CONTACT_694686] 
(n, m ean, SD, m edian, minimum and maximum [and geometric mean and coefficient of 
variat ion, if applicable]) for continuous data and abso lute and relative frequencies for 
categori cal data.
Adverse events will be summarised b y Preferred T erm and System  Organ Class using 
MedDRA  vocabulary . Adverse events that led to wit hdrawal, SAEs, AEs by  [CONTACT_694687]. All AE  summaries will be done by [CONTACT_6490].
Inject ion site reactions will b
e considered an AE of special interest and will be listed 
separately . List ing of inject ion site reactions will include informat ion about size, colour and 
itching status and will be grouped by  [CONTACT_694688] (visit). 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 63of 95Clinical laboratory  data an d ECG param eters will be summarized by [CONTACT_29013].
Use of conco mitant m edicat ion will be reported.
9.5 Interim Analyses
There are no plans to perform any interim analyses during the study .
9.6 Data Monitoring Committee
A data m onitoring committee wi ll not be used in this study .
10. SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 64of 95Appendix ARegulatory, Ethical, and Study Oversight Considerations
A 1 Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizat ions of Medical 
Sciences (CIOMS) International Ethical Guidelines
Applicable ICH GCP Guidelines
Applica ble laws and regulations
The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant 
docum ents (eg, adverti sements) m ust be submitted to an IRB/IEC by  [CONTACT_542424]/IEC before the study  is init iated.
Any amendments to the protocol will require IRB/IEC and applicable Regulatory  
Authori ty approval  before implementati on of  changes m ade to the study  design, except 
for changes necessary  to eliminate an immediate hazard to study  parti cipants.
AstraZene ca will  be responsible for obtaining the required authorisations to conduct the 
study  from the concerned Regulatory  Authori ty. This responsibilit y may be delegated to a 
CRO but the accountabilit y remains wi th [COMPANY_008].
Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by [CONTACT_542425] a SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towards the safet y of parti cipants and the safet y of 
a study  intervent ion under clinical invest igation are m et.
The sponsor has a legal responsibilit y to notify both the l ocal regulatory  authori ty and 
other regulatory  agencies about the safet y of a study  intervent ion under clinical 
investigat ion. The sponsor will co mply with country -specific regulatory  requi rements 
relating to safet y reporting to the regulatory  authorit y, IRB/IEC, and Invest igators.
For all studies except those utilizing medical devices, Invest igator safet y reports m ust be 
prepared for suspected unexpected serious adverse reactions (S[LOCATION_003]R) according to local 
regul atory  requi rements and sponsor policy and forwarded to Invest igators as necessary.
An Invest igator who receives an Investigator safety report describing an SAE or other 
specific safet y informat ion (eg, summary or list ing of SAEs) fro m the spons or will  review 
and then file it along with the Invest igator’s Brochure and will notify the IRB/IEC, if 
appropriate according to local requirements.
A [ADDRESS_942344] igators will provide the sponsor with sufficient, accurate financial 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 65of 95inform ation as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authori ties. Investi gators 
are responsible for providing information on financial intere sts during the course of the study  
and for 1 y ear after com pletion of  the study .
A 3 Informed Consent Process
The Investigator or his/her representative will explain the nature of the study  to the 
participant and answer all quest ions regarding the study.
Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary, and they  are f ree to 
refuse to participate and may wit hdraw their consent at any  time and for any  reason 
during the study . Partici pants will be requi red to sign a statement of informed consent that 
meets the requirements of [ADDRESS_942345] (HIPAA) requirements, where applicable, and the 
IRB/IEC or study  centre.
The m edical  record m ust include a statem ent that wri tten inform ed consent was obtained 
before the participant was enrolled in the study  and the date the written consent was 
obtained. The authorised person obtaining the informed consent must also sign the ICF.
Parti cipants m ust be re -consented to the most cur rent versio n of the ICF(s) during their 
participat ion in the study.
A copy  of the ICF(s) m ust be provi ded to the participant.
Parti cipants who are rescreened are required to sign a new ICF.
The ICF will contain a separate section that addresses and documen ts the collect ion and 
use of any mandatory  and/or opti onal human bio logical samples. The Invest igator or 
authori sed designee will explain to each participant the object ives of the analysis to be 
done on the samples and any potential future use. Participant s will be told that they  are 
free to refuse to participate in any  optional samples or the future use and may wit hdraw 
their consent at any  time and for any  reason during the retenti on peri od. 
A 4 Data Protection
Parti cipants will be assigned a unique ident ifier by [CONTACT_456]. Any part icipant records or 
datasets that are transferred to the sponsor will contain the ident ifier only; part icipant 
names or any  information which would make the participant ident ifiable will not be 
transferred.
The parti cipant m ust b e inform ed that hi s/her personal  study -related data will  be used by  
[CONTACT_456] i n accordance with local data protection law. The level of disclo sure and use 
of their data m ust al so be explained to the participant in the informed consent 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 66of 95The parti cipant must be inform ed that hi s/her m edical  records m ay be examined by 
[CONTACT_17080] y Assurance auditors or other authorised personnel appo inted by  [CONTACT_103], by  [CONTACT_6667]/IEC members, and by [CONTACT_32857].
A 5 Dissemination of Cli nical Study Data
A descri ption of this clinical study  will be available on http://astrazenecaclinicaltrials.com and 
http://www .clinicaltrials.gov as will the summary of the main study  resul ts when they  are 
available. The clinical study  and/or summary  of mainstudy  resul ts may also be available on 
other websites according to the regulat ions of the countries in which the study  is conducted.
A 6 Data Quality Assurance
All participant data relat ing to the study  will be recorded on eCRF unless transmitted to 
the spo nsor or designee electronically (eg, laboratory data). The Investigator is 
responsible for verifying that data entries are accurate and correct by  [CONTACT_592760].
The Investigator must maintain accurate documentation (source data) that supports the 
inform ation entered in the eCRF.
The Investigator must permit study -related m onitoring, audi ts, IRB/IEC review, and 
regul atory  agency inspecti ons and provi de di rect access to source data documents.
Moni toring details describing strategy  (eg, risk -based init iatives in operations and qualit y 
such as Risk Management and Mit igation Strategies and Analyt ical Risk-Based 
Moni toring), m ethods, responsibilit ies and requirements, including handling of 
nonco mpliance issues and monitoring techniques (central, remote, or on -site monitoring) 
are provided in the Moni toring Plan .
The sponsor or designee is responsible for the data management of this study  including 
qualit y checking of the data.
The sponsor assumes ac countabilit y for acti ons delegated to other individuals (eg, CRO).
Study  monitors will perform  ongoing source data verification to confirm that data entered 
into the eCRF by [CONTACT_18029], complete, and verifiable fro m 
source docum ents; that the safet y and ri ghts of  participants are being protected; and that 
the study  is being conducted in accordance with the currently approved protocol and any 
other study  agreem ents, ICH GCP, and all applicable regulatory  requi rements.
Records and docum ents, including signed ICFs, pertaining to the conduct of this study  
must be retained by [CONTACT_13177] 15years after study complet ion unless local 
regul ations or inst itutional policies requi re a l onger retenti on peri od. No records m ay be 
destr oyed during the retention period without the written approval of the sponsor. No 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 67of 95records m ay be transferred to another location or party  without wri tten notificat ion to the 
sponsor.
A 7 Source Documents
Source documents provide evidence for the existence of t he participant and substantiate 
the integrit y of the data collected. Source documents are filed at the Invest igator’s site.
Data reported on the eCRF or entered in the eCRF that are transcribed fro m source 
docum ents m ust be consistent with the source docum ents or the di screpancies must be 
explained. The Invest igator may need to request previous medical records or transfer 
records, depending on the study . Also, current m edical records must be available.
Definit ion of what constitutes source data can be found insource data verificat ion plan.
A [ADDRESS_942346] igator may include but are 
not limited to:
Failure of the Invest igator to comply wit h the protocol, the requirements of the IRB/IEC 
or local health authori ties, the spon sor's procedures, or GCP guidelines
Inadequate recruit ment of parti cipants by  [CONTACT_11856]
Discontinuati on of  further study  intervent ion developm ent
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the 
Invest igato rs, the IECs/IRBs, the regulatory authorit ies, and any CROs used in the study  of the 
reason for terminat ion or suspensio n, as specified by [CONTACT_122644]. 
The Investigator shall pro mptly inform  the parti cipant and shoul d assure appr opriate 
participant therapy  and/or follow -up.
Clinical Study Protocol -2.[ADDRESS_942347] the opportuni ty to be transferred to another site to 
continue the study .
A 9 Publication Policy
The results of this study  may be published or presented at scient ific meetings. If this is 
foreseen, the Invest igator agrees to submit all manuscripts or abstracts to the sponsor 
before submissio n. This allows the sponsor to protect proprietary  information and to 
provi de comments.
The sponsor will co mply wit h the requirements f or publicati on of  study  resul ts. In 
accordance with standard editorial and ethical practice, the sponsor will generally support 
publicat ion of mult icentre studies only  in thei r entirety  and not as individual site data. In 
this case, a coordinat ing Invest igator will be designated by  [CONTACT_357454].
Authorship will be determined by  [CONTACT_73008] h Internat ional 
Committee of Medical Journal Editors authorship requirements.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 69of 95Appendix BAdverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
B [ADDRESS_942348] a 
causal relat ionship with this treatm ent. An AE can therefore be any  unfavourable and 
unintended sign (eg, an abnormal laboratory  finding), symptom (for example nausea, chest 
pain), or disease temporally associated with the use of a medicinal product, whether or not 
considered related to the medicinal product. 
The term  AE is used to include both serious and non -serious AEs and can include a 
deteri oration of  a pre -exist ing medical occurrence. An AE may occur at any  time, including 
run-in or washout periods, even if no S tudy treatment has been administered.
B 2 Definitions of serious adverse event
An SAE is an AE occurring during any  study  phase (i e, run -in, treatment, washout, follow -
up), that fulfils one or more of the fo llowing criteria:
Results in death
Is immediately lif e-threatening
Requi res in -partici pant hospi [INVESTIGATOR_122568] n of exist ing hospi[INVESTIGATOR_72913] 
Results in persistent or significant disabilit y or incapaci ty. 
Is a congenital abnormalit y or birth defect
Is an important medical event that may jeopardise the participant or may require medical 
treatm ent to prevent one of the outcomes listed above.
Adverse Events for malignant tumours reported during a study  shoul d generally be assessed 
as Serious AEs. If no other seriousness criteria apply , the ‘Important Medi cal Event ’ criterion 
shoul d be used. In certain situat ions, however, medical judgement on an individual event basis 
shoul d be applied to clarify  that the malignant tumour event should be assessed and reported 
as a Non-Serious AE. For example , if the tum our is included as medical history and 
progression occurs during the study , but the progressio n does not change treatment and/or 
prognosi s of the m alignant tum our, the AE m ay not fulfil the attributes for being assessed as 
Serious, al though rep orting of the progression of the malignant tumour as an AE is valid and 
shoul d occur .Also, some t ypes of malignant tumours, which do not spread remotely after a 
routi ne treatm ent that does not require hospi[INVESTIGATOR_3094], may be assessed as Non -Serious; 
examp les in adults include Stage 1 basal cell carcino ma and S tage 1A1 cervical cancer 
removed via cone biopsy .
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 70of 95Life threatening
‘Life-threatening ’ means that the participant was at immediate risk of death fro m the AE as i t 
occurred, or it is suspected that use or continued use of the product would result in the 
participant ’s death. ‘Life-threatening ’ does not m ean that had an AE occurred in a more severe 
form it might have caused death (eg, hepatit is that resolved wit hout hepatic failure).
Hospi[INVESTIGATOR_694648] a serious AE, although the reasons 
for it may be (eg, bronchospasm, laryngeal oedema). Hospi[INVESTIGATOR_2144]/or surgical 
operati ons planned before or during a study  are not consi dered AEs if the illnes s or disease 
existed before the participant was enrolled in the study , provi ded that i t did not deteriorate in 
an unexpected way  during the study .
Important medical event or medical treatment
Medical and scientific judgement should be exercised in deciding whether a case is serious in 
situations where important m edical events may  not be immediately life threatening or result in 
death, hospi [INVESTIGATOR_72913], disabili ty or incapaci ty but may jeopardise the participant or may  
requi re medical treatm ent to prevent one or more outcom es listed in the definit ion of seri ous. 
These should usually be considered as serious.
Simply stoppi[INVESTIGATOR_33095]; medical 
judgement must be used.
Angioedema not severe enough to requir e intubation but requiring iv hydrocortisone 
treatm ent
Hepatotoxicit y caused by [CONTACT_33153] l (acetaminophen) overdose requiring treatment with 
N-acetylcysteine
Intensive treatment in an emergency room or at home for allergic bronchospasm
Blood dy scrasias (eg, neutropenia or anaemia requiring blood transfusion, etc) or 
convulsio ns that do not result in hospi[INVESTIGATOR_72913]
Development of drug dependency or drug abuse
Intensity rating scale:
mild (awareness of sign or symptom, but easily tolerated)
moderate (discomf ort sufficient to cause interference with normal act ivities)
severe (incapacitat ing, with inabilit y to perform norm al activities)
Clinical Study Protocol -2.[ADDRESS_942349] inguish between serious and severe AEs. Severit y is a measure of 
intensity whereas seri ousness is defined by [CONTACT_73010] B 2. An AE of severe 
intensity need not necessarily be considered serious. For example, nausea that persists for 
several hours may  be consi dered severe nausea, but not a SAE unless it meets the criteria 
shown in Appendix B
2. On the other hand, a stroke th at results in only a limited degree of 
disabili ty may be considered a mild stroke but would be a SAE when it satisfies the criteria 
shown in Appendix B
2.
B
3 A Guide to Interpreting the Causality Question
When making an assessment of causalit y consi der the foll owing f actors when deciding if there 
is a ‘reasonable possibilit y’that an AE m ay have been caused by [CONTACT_33641].
Time Course. Exposure to suspect drug. Has the participant actually received the suspect 
drug? Did the AE occur in a reasonable temporal relat ionship to the administration of the 
suspect drug?
Consistency wit h known drug profile. Was the AE consistent with the previous 
knowl edge of the su spect drug (pharm acology and toxi cology) or drugs of the same 
pharmaco logical class? Or could the AE be ant icipated from its pharmaco logical 
properties?
De-challenge experience. Did the AE resolve or improve on stoppi[INVESTIGATOR_122570]?
No al ternative cause. The AE cannot be reasonably explained by [CONTACT_73011], other drugs, other host or environmental factors.
Re-challenge experi ence. Di d the AE reoccur if the suspected drug was reintroduced afte r 
having been stopped? [COMPANY_008] would not normally reco mmend or support a re-
challenge .
Laboratory  tests. A specific laboratory  invest igation (if performed) has confirmed the 
relationship .
In difficult cases, other factors could be considered such as:
Is this a recogni sedfeature of overdose of the drug?
Is there a known mechanism?
Causalit y of ‘related ’ is made if fo llowing a review of the relevant data, there is evidence for a 
‘reasonable possibilit y’of a causal relationship for the individual case. The expression 
‘reasonable possibilit y’ of acausal  relati onship is meant to convey , in general, that there are 
facts (evidence) or arguments to suggest a causal relat ionship.
Clinical Study Protocol -2.[ADDRESS_942350] a 
causal relat ionship, the event(s) will be assessed as ‘not rel ated’.
Causal relat ionship in cases where the disease under study  has deteri orated due to l ack of 
effect shoul d be classified as no reasonable possibilit y.
B 4 Medication Error
For the purposes of this clinical study  a medicat ion error is an unintended failure or mistake in 
the treatment process for an [COMPANY_008] study  drug that ei ther causes harm to the participant 
or has the potential to cause harm to the participant. 
A medicat ion error is not lack of efficacy of the drug, but rather a human or process related 
failure while the drug is in control of the study  site staf f or parti cipant.
Medicat ion error includes situat ions where an error . 
occurred
was i dentified and intercepted before the participant received the drug
did not occur, but circumstances were recognised that could have led to an error
Examples of events to be reported in clinical studies as medication errors:
Drug name [CONTACT_33165] n
Dispensing error, eg, medicat ion prepared incorrectly, even if it was not actually given to 
the participant
Drug not administered as indicated, for example, wrong route or wrong site of 
administration
Drug not taken as indicated, eg, tablet disso lved in water when it should be taken as a 
solid tablet 
Drug not stored as instructed, eg, kept in the fridge when it should be at room temperature 
Wrong participant received the medicat ion (excluding RTSM errors)
Wrong drug administered to participant (excluding RTSM errors)
Examples of events that do not require reporting as medicat ion errors in clinical studies:
Errors related to or resulting fro m RTSM -including those which lead to one of the above 
listed events that would otherwise have been a medicat ion error 
Parti cipant acci dentally  missed drug dose(s), eg, forgot to take medication
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 73of 95Accidental  overdose (will be captured as an overdose)
Parti cipant f ailed to return unused medicat ion or empt y packaging
Errors related to background and rescue medicat ion, or standard of care medicat ion in 
open l abel studi es, even if an [COMPANY_008] product 
Medication errors are not regarded as AEs but AEs may occur as a consequence of the medication 
error .
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 74of 95Appendix CHandling of Huma n Biological Samples
C 1 Chain of Custody
A full chain of custody  is maintained for all samples throughout their lifecycle.
The Investigator at each centre keeps full traceability of co llected bio logical sam ples f rom the 
participants while in storage at the ce ntre until shipment or disposal (where appropriate) and 
records relevant processing information related to the samples whilst at site.
The sample receiver keeps full traceabilit y of the sam ples while in storage and during use unt il 
used or disposed of or unt il further shipment and keeps record of receipt of arrival and onward 
shipment or disposal.
[COMPANY_008] or delegated representatives will keep oversight of the ent ire life cycle through 
internal  procedures, m onitoring of study  sites, auditing or process checks, and contractual 
requi rements of external laboratory  provi ders
Samples retained for further use will be stored in the [COMPANY_008] -assigned bi obanks or other 
sample archive facilit ies and will be tracked by  [CONTACT_271130] T eam during for
the rem ainder of the sam ple life cycle.
If required, [COMPANY_008] will ensure that remaining bio logical samples are returned to the site 
according to local regulations or at the end of the retention period, whichever is the sooner .
C 2 Withdrawal of Informed Consent for Donated Biological Samples 
If a participant withdraws consent to the use of donated bio logical  samples, the sam ples will 
be disposed of/destroy ed/repatriated, and the action documented. If samples are already  
analysed ,[COMPANY_008] is not oblig ed to destroy  the resul ts of this research.
Following wi thdrawal  of consent for bio logical samples, further study  partici pation shoul d be 
considered in relat ion to the wi thdrawal  processes outlined in the informed consent.
The Investigator:
Ensures partici pant’s wi thdrawal of informed consent to the use of donated samples is 
highlighted immediately to [COMPANY_008] or delegate.
Ensures that relevant human bio logical samples from  that parti cipant, if stored at the 
study  site, are immediately  identified, disposed of as appropriate, and the action 
docum ented
Ensures that the participant and [COMPANY_008] are informed about the sample disposal.
Clinical Study Prot ocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 75of 95[COMPANY_008] ensures the organizat ion(s) ho lding the samples is/are informed about the 
withdrawn consent immediately and that sam ples are disposed of or repatriated as appropriate, 
and the action documented, and study  site notified.
C 3 International Airline Transportation Association (IATA) 6.[ADDRESS_942351] SAMPLES
International Airl ine Transportation Associat ion (IA TA) 
(https://www .iata.org/whatwedo/cargo/dgr/Pages/download.aspx ) classifies infect ious 
substances into 3 categories: Category  A, Category B or Exempt
Category A Infectious Substances are infect ious substances in a form th at, when exposure to 
it occurs, i s capable of causing permanent disabilit y, life-threatening or fatal disease in 
otherwi se healt hy humans or animals. 
Category A pathogens are, for example, Ebola, Lassa fever virus. Infectious substances 
meet ing these crit eria which cause disease in humans or both in humans and animals must be 
assigned to UN 2814. Infect ious substances which cause disease only in animals must be 
assigned to UN 2900:
Category B Infectious Substances are infect ious Substances that do not meet the criteria for 
inclusio n in Category  A. Category  B pathogens are, for example, Hepatit is A, C, D, and E 
viruses. They are assigned the fo llowing UN number and proper shippi[INVESTIGATOR_72919]
UN 3373 –Biological Substance, Category  B
are to be packed in accordance with UN3373 and IATA [ADDRESS_942352] to these Regulations unless they  
meet the criteria for inclusio n in another cla ss.
Clinical study samples will fall into Category  B or exempt under IATA regulat ions
Clinical study  samples will routinely  be packed and transported at ambient temperature in 
IATA 650 compliant packaging 
(https://www.iata.org/whatwedo/cargo/dgr/Documents/ DGR -60-EN-PI650.pdf).
Biological samples transported in dry  ice requi re addi tional dangerous goods specificat ion 
for the dry -ice content
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 76of 95Appendix DOptional Genomics Initiative Sample 
D 1 Use/analysis of DNA
Genet ic variat ion may impact a participant ’s response to therapy , suscept ibilit y to, and 
severit y and progressi on of  disease. V ariable response to therapy  may be due to genetic 
determinants that impact drug absorption, distributio n, metabo lism, and excret ion; mechanism  
of action of  the drug; disease aet iology; a nd/or m olecular subt ype of the disease being treated. 
Therefore, where local regulat ions and IRB/IEC allow , a bl ood sam ple will  be collected for 
DNA  analysis fro m consent ing participants.
[COMPANY_008] intends to collect and store DNA  for genet ic research to explore how genetic 
variat ions may affect clinical parameters, risk and prognosis o f diseases, and the response to 
medicat ions. Genet ic research may lead to better understanding of diseases, better diagnosis of 
diseases or other improvements in healt h car e and to the di scovery  of new diagnosti cs, 
treatm ents or m edicat ions.
In addit ion, collect ion of DNA  samples from  populati ons wi th well described clinical 
characterist ics may lead to improvements in the design and interpretation of clinical trials and, 
possibly, to geneti cally gui ded treatm ent strategi es.
Genet ic research may consist of the analysis o f the structure of the participant ´s DNA, ie, the 
entire geno me. 
The results of genet ic analyses may be reported in the CSR or in a separate study summary . 
The sponsor will store the DNA  samples in a secure storage space with adequate measures to 
protect confident iality. The samples will be retained while research on AZD8233 or other 
[COMPANY_008] Study  treatm ents of thi s class or for this indicat ion continues bu t no l onger than 
[ADDRESS_942353] fulfil all of the inclusio ncriteria 
described in the main body  of the Clinical Study  Protocol  and: Provi de informed consent for 
the Geno mics Init iative sampling and analyses.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 77of 95Exclusion Criteria
Exclusio n from this genet ic research may be for any o f the excl usion criteria specified in 
the main study  or any  of the f ollowing:
Previous allogeneic bone marrow transplant
Non-leukocyte depleted whole blood transfusio n wit hin [ADDRESS_942354] ion
Healthy Vol unteers and paediatric pat ient samples will  not be coll ected for th e 
Geno mics Init iative.
Withdrawal of consent for genetic research:
Parti cipants may  withdraw from  this genet ic research at any t ime, independent of any decisio n 
concerning participat ion in other aspects of the main study. V oluntary  withdrawal will not 
prejudice further treatment. Procedures for withdrawal of consent are outlined in 
Appendix C 2.
Collection of samples for genetic research
The blood sample for genet ic research will preferably be obtained fro m the parti cipants at 
Visit 3 predose. If, for any  reason, the sam ple is not drawn pre -dose on Visit 3 (D1), it may be 
taken at any  visit until the Final follow -up/EDV visit. Although DNA  is stable, early sample 
collect ion is preferred to avo id int roducing bias through excluding participants who may 
withdraw due to an adverse event (AE), such participants would be important to include in 
any genet ic analysis. If for any reason the sample is not drawn at the screening v isit, i t may be 
taken at any  visit until the l ast study  visit. Only one sample should be collected per participant 
for genet ics during the study . Sam ples will be co llected, labelled, stored, and shipped as 
detailed in the Laboratory  Manual.
Coding and stor age of DNA samples
The process adopted for the single coding and storage of samples for genet ic analysis are 
important to maintain participant confident iality. Sam ples will  be stored for a m aximum  of [ADDRESS_942355] acing the information on the sample tube. Thereafter, the sample will be 
ident ifiable only by [CONTACT_33160], unique number . This number is used to ident ify the sample 
and corresponding data at the [COMPANY_008] genet ics laboratori es, or at the desi gnated 
organisat ion. No personal details ident ifying the individual will be available to any person 
([COMPANY_008] emplo yee or designated organisat ions working with the DNA).
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 78of 95The link between the partic ipant enrollment/randomizat ion code and the second number will 
be maintained and stored in a secure environment, with restricted access at [COMPANY_008] or 
designated organisat ions. The link will be used to ident ify the relevant DNA  samples for 
analysis, fac ilitate correlat ion of genoty pic resul ts wi th clinical  data, all ow regulatory  audi t, 
and permit tracing o f samples for destruction in the case of withdrawal of consent.
Ethical and regulatory requirements
The principles for ethical and regulatory  requi reme nts for the study , including this genetics 
research component, are outlined in Appendix A.
Informed consent
The genetic component of this study  is opti onal and the participant m ay part icipate in other 
components of the m ain study  without parti cipat ing in this genet ic co mponent . To parti cipate 
in the genet ic co mponent of the study , the parti cipant m ust si gn and date both the consent 
form for the m ain study  and the add endum for the Geno mics Init iative component of the 
study . Copi [INVESTIGATOR_694649]. The Principal Investigator(s) is responsible for ensuring that 
consent is g iven freely and that the participant understands that they  may freely wi thdrawal  
from the genetic aspect of the study  at any  time.
Participant data protection
[COMPANY_008] will not provide individual genoty pe resul ts to parti cipants, any  insurance 
company, any empl oyer, their family members, general physician unless required to do so by 
[CONTACT_2371].
Extra precautions are taken to preserve confident iality and prevent genetic data being linked to 
the identi ty of the parti cipant. In except ional circumstances, however, certain individuals 
might see both the genet ic data and the personal ident ifiers of a participant. For example, in 
the case of a medical emergency , an [COMPANY_008] Physician or an Invest igator might know a 
participant ’s identity and also have access to his or her genet ic data. In addit ion, Regulatory  
authori ties may  requi re access to the rel evant files, though the participant ’s medical 
inform ation and the genet ic files would remain physically separate.
Data management
Any genoty pe data generated in this stud y will be stored at a secure system at [COMPANY_008] 
and/or designated organisat ions to analyse the samples.
[COMPANY_008] and its designated organisat ions may share summary results (such as genet ic 
differences fro m groups of individuals wit h a di sease) fro m this genetic research with other 
researchers, such as hospi[INVESTIGATOR_600], academic organisat ions or health insurance co mpanies. This can 
be done by [CONTACT_103472], where they can be combined with the 
Clinical Study Protocol -2.[ADDRESS_942356] ical 
Analysis Plan ma y be prepared where appropriate.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 80of 95Appendix EActions Required in Cases of Increases in Liver Biochemistry 
and Evaluation of Hy’s Law
E [ADDRESS_942357] igator is responsible for determining whe ther a parti cipant meets PHL  
criteria at any  point during the study .
All sources of l aboratory  data are appropri ate for the determinat ion of PHL  and HL  events; 
this includes samples taken at scheduled study  visits and other vi sits including central  and all
local laboratory  evaluat ions even if co llected outside of the study  visit s; for exam ple, PHL  
criteria coul d be m et by  [CONTACT_96724] a central  laboratory  and/or elevated TBL  from 
a local laboratory . 
The Investigator will also review Adverse Event d ata (for example, for AEs that may indicate 
elevations in liver biochemistry ) for possible PHL  events.
The Investigator participates, together with [COMPANY_008] clinical project representatives, in 
review and assessment of cases meet ing PHL  criteria to agre e whether HL  criteria are m et. HL  
criteria are met if there is no alternat ive explanation for the elevat ions in liver biochemistry  
other than DILI caused by  [CONTACT_592730]. 
The Investigator is responsible for recording data pertaining to PHL/HL  cases and for 
reporting SAEs and AEs according to the outcome of the review and assessment in line with 
standard safet y reporting processes.
E 2 Definitions
Potential Hy’s Law
AST or ALT ≥ 3 ×ULN together  with TBL ≥ 2 × ULN at any  point during the study  
following the start of study  medicat ionirrespect ive of an increase in ALP .
Hy’s Law
AST or ALT ≥ 3 × ULN together  with TBL ≥ 2 × ULN, where no other reason, other than the 
IMP, can be found to explain the co mbinat ion of increases, eg, elevated ALP indicat ing 
cholestasis, vi ral hepat itis, another drug. 
For PHL  and HL  the el evation in transaminases must precede or be coincident with (ie, on the 
same day ) the el evati on in TBL, but there is no specified timeframe within which the 
Clinical Study Protocol -2.[ADDRESS_942358] occur .
E 3 Identification of Potential Hy’s Law Cases
In order to i dentify  cases of PHL  it is important to perform a comprehensive review of 
laboratory  data for any  parti cipant who m eets any of the fo llowing identificat ion criteria in 
isolation or in com binat ion:
ALT ≥ 3 × ULN
AST ≥ 3 × ULN
TBL ≥ 2 × ULN
Central laboratories being used:
When a participant meets any of the PHL  identification criteria, in iso lation or in co mbinat ion, 
the central  laboratory  will immediately send an alert to the Invest igator (also sent to 
[COMPANY_008] representative). 
The Investigator will also remain vigilan t for any  local  laboratory  reports where the PHL  
ident ificat ion criteria are met, where this is the case the Investigator will:
Notify  the [COMPANY_008] representative 
Request a repeat of the test (new blood draw) by  [CONTACT_531440]
Com plete the appropri ate unscheduled laboratory  eCRF m odule(s) wi th the 
original  local laboratory  test resul t
When the identificat ion criteria are m et from central  or local laboratory  resul ts the Invest igator 
will wit hout del ay:
Determine whether the partici pant m eets PHL cri teria (see Section E 2for 
definit ion) by  [CONTACT_42574] l aboratory  reports from  all previ ous visi ts (including both 
central  and l ocal laboratory  resul ts)
E 4 Follow -up
E4.1 Potential Hy’s Law Criteria not met
If the participant does not meet PHL  criteria the Investi gator will:
Inform  the [COMPANY_008] representative that the participant has not met PHL criteria.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 82of 95Perform  follow-up on subsequent lab oratory  resul ts according to the guidance provided in 
the CSP.
E4.2 Potential Hy’s Law Criteria met
If the participant does meet PHL  criteria the Investigator will:
Notify  the [COMPANY_008] representative who will then inform the Glo bal Study  Team  
Within [ADDRESS_942359] igator will report the case as an SAE of 
PHL; serious criteria ‘Important m edical  event ’ and causalit y assessment ‘yes/related’ 
according to CSP process for SAE reporting.
For parti cipants that met PHL  criteria prior to starting IMP , the Investigator is not 
requi red to submit a PHL  SAE unless there is a significant change #in the participant ’s 
condi tion
The Study  Physician contacts the Invest igator , to provide guidance, discuss and agree an 
approach for the study  parti cipants ’ follow-up (including any  further laboratory  testing) 
and the continuous review of data
Subsequent to this contact [CONTACT_73016]:
Moni tor the parti cipant until liver bio chemistry  param eters and appropri ate clinical 
symptoms and signs return t o norm al or baseline levels, or as l ong as m edically 
indicated. Completes fo llow-up SAE Form as required.
Invest igate the aetiology o f the event and perform diagnostic investigat ions as 
discussed wi th the Study  Physician. This includes deciding which of th e tests 
available in the HL lab kit should be used. 
Com plete the three Liver eCRF Modules as information beco mes available 
#A ‘significant ’ change in the participant ’s condi tion refers to a clinically  relevant 
change in any  of the individual liver bioch emistry  param eters (AL T, AST or total bilirubin) in 
isolation or in combinat ion, or a clinically  relevant change in associated symptoms. The 
determinat ion of whether there has been a significant change will be at the discret ion of the 
Invest igator , this ma y be in consultat ion with the Study  Physician if there is any  uncertaint y.
E 5 Review and Assessment of Potential Hy’s Law Cases
The instructions in this Section should be fo llowed for all cases where PHL  criteria are m et.
As soon as possible after the biochemistry  abnormalit y was ini tially detected, the Study  
Physician contacts the Invest igator in order to review available data and agree on whether 
Clinical Study Protocol -2.[ADDRESS_942360] and TBL elevat ions, a 
determinat ion of whether the alternat ive explanat ion is an AE will be made and subsequent ly 
whether the AE meets the criteria for a SAE:
If the alternat ive explanat ion is notan AE, record the alternative explanation on the 
appropriate eCRF
If the alternat ive explanat ion is an AE/ SAE: update the previously submitted PHL SAE 
and AE eCRFs accordingly wit h the new informat ion (reassessing event term; causalit y 
and seriousness criteria) fo llowing the [COMPANY_008] standard processes.
If it is agreed that there is no explanat ion that wou ld explain the AL T or AST and TBL  
elevations other than the study  treatm ent:
Send updated SAE (report term ‘Hy’s Law’) according to [COMPANY_008] standard 
processes. 
 The ‘Medically  Important’ seri ous cri terion shoul d be used if no other serious 
criteria app ly
 As there is no alternat ive explanation for the HL case, a causalit y assessment of 
‘related’ should be assigned.
If, there i s an unavo idable delay , of over 15 cal endar day s in obtaining the informat ion 
necessary  to assess whether or not the case meets t he criteria for HL, then it is assumed that 
there is no alternat ive explanation unt il such time as an informed decisio n can be made:
Provi des any  further update to the previously submitted SAE of Potential Hy’s Law, 
(report term now ‘Hy’s Law case’) ensuri ng causalit y assessment i s related to study  
treatm ent and seri ousness cri teria is m edically important, according to CSP process for 
SAE reporting.
Continue fo llow-up and review according to agreed plan. Once the necessary  
supplementary  informat ion is obtained, repeat the review and assessment to determine 
whether HL criteria are still met. Update the previously submitted PHL SAE report 
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 84of 95following CSP process for SAE reporting, according to the outcome of the review and 
amending the reported term if an a lternat ive explanat ion for the liver biochemistry  
elevations is determined.
E 6 References
Aithal et al, 2011
Aithal et al 2011, Clinical Pharmaco logy and Therapeutics 89(6):806 -815.
FDA Guidance for Industry, July 2009
FDA  Guidance for Industry  (issued July 2009) ‘ Drug -induced liver injury: Premarket ing 
clinical evaluat ion’. Available fro m; https://www .fda.gov/regulatory -informat ion/search -fda-
guidance -docum ents/drug -induced -liver-injury -premarket ing-clinical -evaluati on
Clinical Study Protocol -2.[ADDRESS_942361] ment of monitoring 
frequency  (platel et count < 100,000/µL), assessment of addit ional laboratory  parameters 
(platelet count < 75,000/µL), referral to a haematologist (platelet count ≤ 50,000/µL) and start 
of supportive treatment with corticosteroids (platelet count ≤ 30,000/µL). Drug 
discontinuation according to the defined stoppi[INVESTIGATOR_694650].
F [ADDRESS_942362] likely  caused by  a 
combinat ion of ASO -induced ant iplatelet immunogl obulin G (IgG) antibodies and the 
anticoagulant EDT A. If there is suspi[INVESTIGATOR_24510] n of EDT A-mediated platelet clumpi[INVESTIGATOR_007], a repe at 
platelet count using a different anticoagulant, eg, sodium citrate or heparin, should be done as 
soon as possible and always before a new dose is given.
Thrombocyte Monitoring Fr equency
Platelet Count (per µL) Monitoring Frequency
>100,000 Every 2 weeks
≥75,000 to < 100,000 or more than 50% reduction 
from baselineEvery week
<75,000 Intensified monitoring; twice weekly to daily 
monitoring dependent of platelet count and rate of 
decline
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 86of 95Additional Laboratory Assessments (Platelet Count <75,000/ μL)
Peripheral smear 
Fibrinogen split products or D -dimer on fresh blood 
Citrated sample for platelets
Coagulation panel (PT/INR, aPTT)
CBC with reticulocytes and mean platelet volume (MPV)
Serum B12 and folate
Fibrinogen
von Willebrand factor
Total globulins, total IgA, IgG, and IgM
Complement: total C3, total C4, Bb, C5a 
hs-CRP
Serology for:
HBV , HCV , HIV (if not done for screening)
Rubella
CMV
EBV
Parvo B19
Helicobacter pylori (IgG serum test)
Auto-antibody screen:
Antiphospholipid
Rheumatoid factor
Anti-dsDNA
Anti-thy roid
To be performed at specialty lab(s):
Antiplatelet antibodies and Anti -PF4 assay
Anti-drug antibody 
F [ADDRESS_942363] Care
Parti cipants that devel op thrombocy topeni a with platel et counts ≤ 50,000/µL shoul d be 
referred to a Haematologist for diagnost ic and therapeutic management. This may include the 
additional laboratory  tests described in the table above. Addit ional bone marr ow aspi[INVESTIGATOR_694651].
Supportive T reatment with Corticoster oids
Treatment of severe thrombocytopenia requires close communicat ion amo ng consult ing 
specialists. For major or life -threatening bleeding, platelet transfusio ns should be administered 
Clinical Study Protocol -2.[ADDRESS_942364] been associated with immune -mediated throm bocy topenia 
it is strongly  recommended that parti cipants wi th platel et counts ≤ 30,000/µl receive 
glucocorti coid therapy (unless contraindicated). High dose steroids h ave been reported to 
reverse platelet decline and accelerate platelet recovery . Treatment guidelines for  immune 
thrombocytopenia recommend: Dexamethasone 40mg daily for 4 days every 2 to4weeks 
for 1to4 cycles; Prednis(ol)one 0.5to2mg/kg/day  for 2to4 weeks then taper; or 
Methylpredniso lone 30 mg/kg/day for 7 days (may require cont inuation wit h oral  steroi ds 
after m ethylpredniso lone) (Provan et al, 2010). Pl atelet count should be monitored closely 
during corticosteroid treatment. An increased or normalized platelet count is expected within 
two weeks of therapy . Once the pl atelet count normali zes or ri ses significantly and plateaus 
>50,000/µl, no addit ional therapy  is needed. Participants should be followed until platelet 
count has been > 100,000/µl for  1 month (see above table for monitoring frequency).
F [ADDRESS_942365] igation and m anagement of 
primary  immune thrombocy topeni a. Bl ood. 2010;1 15(2):168 -186.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 88of 95Appendix GGuidance for Definition of Anaphylactic/Hypersensitivity 
Reactions and Checklist for the Investigator
The National Inst itute of Allergy and Infect ious Disease and Food Allergy and Anaphylaxis 
Network Guidance for Anaphylaxis Diagnosis define anaphylaxis as a serious allergic reaction 
that is rapid in onset and may  cause death. They  recogni ze 3 categori es of anaphylaxis, with 
criteria designated to capture from 80% of cases (category  1) to > 95% of all cases of 
anaphylaxis (for all 3 categories). Refer to Sampson et al, 2006 .
1Acute onset of an illness (minutes to several hours) with invo lvement of the skin, mucosal 
tissue, or both (eg, generalized hives, pruritus or flushing, swo llen lips -tongue -uvula) and 
at least one of the following :
(a)Respi[INVESTIGATOR_33097] (eg, dyspnoea , wheeze -bronchospasm, stridor, reduced PEF, 
hypoxemia)
(b)Reduced BP or associated symptoms of end -organ dy sfunct ion (eg, hy potoni a 
[collapse], syncope, incont inence).
2Two or more of the fo llowing that occur rapi[INVESTIGATOR_11312] a likely allergen for th at 
participant (minutes to several hours):
(a)Involvement of the skin -mucosal t issue (eg, generalized hives, itch -flush, swollen 
lips-tongue-uvula)
(b)Respi[INVESTIGATOR_33097] (eg, dyspnoea, wheeze- bronchospasm, stridor, reduced PEF, 
hypoxemia)
(c)Reduced BP or assoc iated symptoms (eg, hy potonia [coll apse], syncope, 
incont inence)
(d)Persi stent gastrointestinal symptoms (eg, crampy  abdominal  pain, vomi ting)
3Reduced BP after exposure to known allergen for that participant (minutes to several 
hours):
(a)Infants and children: l ow SBP (age specific) or greater than 30% decrease in SBP.
(b)Adults: SBP of less than 90 mmHg or greater than 30% decrease fro m that person’s 
baseline.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 89of 95Hypersensitivity Reactions –Checklist for The Investigator 
At least the following should be checked. If “Yes” the diagnosis (preferably not symptoms) should 
be recorded as AE.
Yes No
Skin and subcutaneous events 
Urticaria 
Erythema 
Pruritus 
Face oedema 
Eye oedema 
Tongue swelling 
Angioedema 
Respi[INVESTIGATOR_694652] -2.[ADDRESS_942366] ic-like 
reaction, if feasible.
G 1 Reference
Sampson et al, 2006
Sampson HA  et al.Second symposium on the definit ion and management of anaphylaxis: 
Summary  report -Second National Inst itute of Allergy  and Infect ious Disease/Food Allergy 
and Anaphylaxis Network sympos ium. J Allergy Clin Immuno l. 2006;117:391 -397.
Clinical Study Prot ocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 91of 95Appendix HHigh -and Moderate -intensity Statin Therapy
Parti cipants shoul d be receiving moderate -or high-intensit y statin therapy  as defined by [CONTACT_277511]/AHA  guidelines on blood cholesterol management, or according to lo cal guidelines. 
Below are examples of high -and moderate -intensity  statin therapy  for ref erence.
High -dose Statin Therapi[INVESTIGATOR_694653] -dose Statin Therapi[INVESTIGATOR_014]
• atorvastatin 40 to 80 mg once daily
• rosuvastatin 20 to 40 mg once daily• atorvastatin 10 to 20 mg once daily
• lovastatin 40 mg once daily
• pravastatin 40 mg once daily
• rosuvastatin 5 mg once daily
• rosuvastatin 5 to 10 mg daily
• simvastatin 20 to 40 mg once daily.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 92of 95Appendix IAbbreviations
Abbreviation or special 
termExplanation
ACC/AHA American College of Cardiology/American Heart Association
AE Adverse Event
ADA Anti-drug antibody
ALP Alkaline Phosphatase
ALT Alkaline Aminotransferase
Apo Apolipoproteins
aPTT Activated Partial Thromboplastin Time
ASO Antisense Oligonucleotide
AST Aspartate Aminotransferase
BMI Body Mass Index
BP Blood Pressure
bpm Beats Per Minute
BUN Blood Urea Nitrogen
CI Confidence Interval
CK Creatine Kinase
CRO Contract Research Organisation
CSA Clinical Study Agreement
CSP Clinical Study Protocol
CSR Clinical Study Report
CVD Cardiovascular Disease
DBP Diastolic Blood Pressure
DILI Drug Induced Liver Injury
EC Ethics Committee, synonymous to Institutional Review Board (IRB) and 
Independent Ethics Committee (IEC)
ECG Electrocardiogram
eCRF electronic Case Report Form
EDC Electronic Data Capture
EDTA Ethylenediaminetetraacetic Acid
EDV Early  Discontinuation Visit
eGFR Estimated Glomerular Filtration Rate
FDA U.S. Food and Drug Administration
FSH Follicle -stimulating Hormone
GCP Good Clinical Practice
GGT Gamma Glutamyl Transpeptidase
Clinical Study Protocol -2.[ADDRESS_942367] Haematocrit
HDL -C High -density Lipoprotein Cholesterol
HIV Human Immunodeficiency Virus
HL Hy’s Law
HMG -CoA 3-hydroxy -3-methy l-glutary lcoenzy me A
HR Heart Rate
hs-CRP High sensitive C -reactive Protein
IATA International Airline Transportation Association
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Council for Harmonisation
IRB/IEC Institutio nal Review Boards/Independent Ethics Committees
ISR Injection Site Reaction
IUD Intrauterine Device
LDL Low-density  Lipoprotein Cholesterol
LDL -C Low-density  Lipoprotein Cholesterol
LH Luteinizing Hormone
LLN Lower Limit of Normal
Lp(a) Lipoprotein(a)
MCH Mean Corpuscular Haemoglobin
MCHC Mean Corpuscular Haemaglobin Concentration
MCV Mean Corpuscular Volume
NHP Non-compliance Handling Plan
PCSK9 Proprotein Convertase Subtilisin/Kexin type -9
PEF Peak Expi[INVESTIGATOR_694654]’s Law
PI [INVESTIGATOR_694655] -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 94of 95Abbreviation or special 
termExplanation
SAE Serious Adverse Event 
SBP Systolic Blood Pressure
SC Subcutaneous(ly)
SD Standard Deviation
SEM Standard Error of the Mean
SoA Schedule of Activities
TBL Total Bilirubin
TC Total cholesterol
UACR Urine Albumin to Creatinine Ratio
ULN Upper Limit of Normal
UPCR Urine Protein to Creatinine Ratio
VLDL -C Very -low-density lipoprotein cholesterol
WBC White Blood Cell
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 95of 9511. REFERENCES
Burdick AD et al 2014
Burdi ck AD et al. Sequence motifs associated with hepatotoxicit y of locked nucleic acid 
modified ant isense o ligonucleotides. Nucleic Acid Res. 2014; 42:4882-4891.
Burel S et al [ADDRESS_942368] ivator of transcript ion 3 in 
mice and cyno molgus monkeys. Nucleic Acid Ther. 2013; 23:213 -227.
Cohen J et al 2005
Cohen J et al. Low LDL  cholesterol in individuals of African descent result ing from frequent 
nonsense mutations in PCSK9. Nat Genet. 2005; 37:[ADDRESS_942369] coronary  heart 
disease. N Engl  J Med 2006; 354:1264 -1272.
Collins R et al 2016
Collins R et al. Interpretation of the evidence for the efficacy and safet y of statin therapy . 
Lancet. 2016; 388:[ADDRESS_942370] et al. Integrated safet y assessment of 2'-O- methoxyethyl chimeric ant isense 
oligonucleotides in non -human primates and healt hy human vo lunteers. Mol  Ther. 2016; 
10:1771-1782.
Crooke ST et al [ADDRESS_942371] et al. The effects of 2′-O- methoxyethyl containing antisense oligonucleotides on 
platelets in human clinical trials. Nucleic Acid Ther . 2017; 27:121 -129.
Hagedorn PH et al 2013
Hagedorn PH et al. Hepatotoxic potential o f therapeuti c oligonucleoti des can be predicted 
from their sequence and m odificat ion pattern. Nucleic Acid Ther . 2013; 23(5):302 -310.
Henry SP et al 1997
Henry  SP et al . Inhibi tion of coagulati on by  a phosphorothi oate oligonucleoti de. Antisense 
Nucl eic Drug Dev . 1997; 7(5):[ADDRESS_942372] s of 2′-methoxyethyl antisense oligonucleotides on 
platelet count in cyno molgus nonhuman primates. Nucleic Acid Ther . 2017; 27(4):197 -208.
Clinical Study Protocol -2.0 [COMPANY_008]
AZD8233 -D7990C00003
CONFIDENTIAL AND PROPRIETARY 96of 96Hildebrandt Eriksen ES et al 2012
Hildebrandt Eriksen ES et al. A locked nucleic acid oligonucleotide targeting microRNA  122 
is well tolerated in cyno molgus monkeys. Nucleic Acid Ther . 2012; 22:152 -156.
Hung G et al 2013
Hung G et al. Characterizat ion of target mRNA  reducti on through in situ RNA  hybridizati on 
in multiple organ systems fo llowing systemic ant isense tr eatment in animals. Nucleic Acid 
Ther. 2013; 23(6):369 -378.
Investigator’s Brochure [ADDRESS_942373] igator’s Brochure. AZD8233/AZD6615, Edition 1.1, dated 23 May 2019.
Prakash TP et al 2014
Prakash TP et al. T argeted delivery of ant isense oligonucleotides to he patocy tes using 
triantennary  N-acetyl galactosamine improves potency 10 -fold in mice. Nucleic Acids Res 
2014; 42:8796 -8807.
Ray KK et al 2017
Ray KK et al . Inclisiran in pat ients at hi gh cardio vascular ri sk wi th elevated LDL  chol esterol . 
N Engl  J Med 2017; 376:1430-1440.
Sabatine MS et al 2017
Sabat ine MS et al. Evolocumab and clinical outcomes in patients with cardio vascular disease. 
N Engl  J Med. 2017; 376:1713 -1722.
Sewell KL et al 2002
Sewell KL  et al . Phase 1 tri al of ISIS 104838, a 2′-methoxyethyl modified antisense 
oligonucleotide targeting tumor necrosis factor- alpha. J Pharmaco l Exp Ther . 2002; 303:1334 -
1343.
Sheehan JP, Lan HC 1998
Sheehan JP , Lan HC Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. 
Blood. 1998; 92:1617 -1625.
Sheehan JP, Thao PM 2001
Sheehan JP , Thao PM Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex 
by [CONTACT_694689] . Biochemistry . 2001; 40:4980 -
4989.
Van Meer L et al 2017
Van Meer L  et al . Novel  SGL T2 inhibitor: first in man studi es of antisense co mpound is 
associ ated wi th unexpected renal effects. Pharmacol Res Perspect. 2017; 17:e0029
Clinical Study Protocol -2.[ADDRESS_942374] PCS K9. Am J Kidney Dis. 2013; 62:[ADDRESS_942375] EP  et al . Ant isense mediated reduction of proprotein convertase subt ilisin/kexin 
type 9 (PCSK9): a first in human rando mized, placebo controlled trial. Br J Clin Pharmaco l. 
2015; 80:[ADDRESS_942376] that was signed
electronically and this page is the manifestation of the electronic signature
[CONTACT_24558]: d7990c00003-csp-v2
Document Title: D7990C00003 Clinical Study Protocol version 2
Document ID: Doc ID-004249727
Version Label: 3.[ADDRESS_942377] APPROVED
Server Date
(dd-MMM-yyyy HH:mm ‘UTC’Z)Signed by [CONTACT_24557]
21-Dec-2020 12:06 UTC Author Approval
21-Dec-2020 10:26 UTC Author Approval
18-Dec-2020 15:57 UTC Qualified Person Approval
18-Dec-2020 06:38 UTC Content Approval
Notes: (1) Document details as stored in ANGEL, an [COMPANY_008] document management system.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]